<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Initial treatment of chronic myeloid leukemia in chronic phase
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Initial treatment of chronic myeloid leukemia in chronic phase
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Initial treatment of chronic myeloid leukemia in chronic phase
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Charles A Schiffer, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Ehab Atallah, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard A Larson, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan G Rosmarin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 17, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm associated with the Philadelphia chromosome t(9;22)(q34;q11) and the
         <em>
          BCR::ABL1
         </em>
         fusion gene, which produces a constitutively active BCR::ABL1 tyrosine kinase. Most patients present in chronic phase (CP) CML, which is typically manifest as leukocytosis and immature myeloid cells in peripheral blood, with or without anemia, thrombocytopenia, constitutional symptoms, splenomegaly, and/or bleeding. CP CML can progress from a relatively indolent disorder to the more aggressive disorders, accelerated phase or blast crisis.
        </p>
        <p>
         The initial treatment of CP CML will be discussed here.
        </p>
        <p>
         Clinical presentation and diagnosis of CML, treatment of relapsed/resistant CML, and management of accelerated phase and blast crisis are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4543.html" rel="external">
          "Clinical manifestations and diagnosis of chronic myeloid leukemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4515.html" rel="external">
          "Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4514.html" rel="external">
          "Accelerated phase chronic myeloid leukemia: Diagnosis and treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4512.html" rel="external">
          "Treatment of chronic myeloid leukemia in blast crisis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1451513241">
         <span class="h1">
          GOALS OF CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The goals of care for patients with CP CML are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For all patients for management of chronic phase CML are to achieve clinical remission, maintain long-term disease control, and avoid disease progression to an accelerated phase or blast crisis, while optimizing quality of life by limiting treatment-related toxicity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who achieve a sustained and deep molecular remission, a trial of discontinuation of therapy to achieve a treatment-free remission (TFR) is a long-term goal of management. Criteria for considering a trial of tyrosine kinase inhibitor (TKI) discontinuation are described below. (See
         <a class="local">
          'TKI discontinuation for TFR'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Milestones for hematologic, cytogenetic, and molecular responses  (
         <a class="graphic graphic_table graphicRef90430" href="/z/d/graphic/90430.html" rel="external">
          table 1
         </a>
         ), which are surrogates of disease control, are described below. (See
         <a class="local">
          'Treatment response'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H693346417">
         <span class="h1">
          PRETREATMENT EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H2808424545">
         <span class="h2">
          Clinical and laboratory evaluation
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical
         </strong>
         – History should determine performance status  (
         <a class="graphic graphic_table graphicRef57945" href="/z/d/graphic/57945.html" rel="external">
          table 2
         </a>
         ) and identify medical comorbidities, current medications, cardiovascular risk factors, and insurance status. Physical examination must include documentation of blood pressure and measurements of liver and spleen size (below the costal margin) by palpation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Laboratory studies
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Complete blood count (CBC) with differential count.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Serum chemistries – Electrolytes, renal and liver function tests, uric acid, lactate dehydrogenase.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hepatitis B panel – HBsAg, HBsAb, anti-HBc IgM and IgG antibodies; reactivation of hepatitis B in association with tyrosine kinase inhibitor (TKI) therapy has been described in case reports, but the risk is not well-defined.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Electrocardiogram (EKG) to measure baseline QTc interval; some clinicians obtain an EKG only in patients who will be treated with
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         or
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         . (See
         <a class="local">
          'Society guideline links'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           BCR::ABL1
          </em>
         </strong>
         – Quantitative reverse-transcription polymerase chain reaction (qRT-PCR) for
         <em>
          BCR::ABL1
         </em>
         should be performed prior to initiation of a TKI, to establish that quantifiable transcripts can be identified using a standard primer pair and to enable molecular monitoring of response. (See
         <a class="local">
          'Treatment response'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bone marrow examination
         </strong>
         – Bone marrow should be examined for morphology (eg, fibrosis, blast count) and cytogenetics as a baseline measure. Some experts consider that bone marrow examination is not required if CP CML was diagnosed on the basis of cytogenetics and polymerase chain reaction (PCR) from peripheral blood. (See
         <a class="medical medical_review" href="/z/d/html/4543.html" rel="external">
          "Clinical manifestations and diagnosis of chronic myeloid leukemia", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients who are found to have additional cytogenetic abnormalities (ie, cytogenetic abnormalities in addition to t(9;22)) are discussed below. (See
         <a class="local">
          'Additional chromosomal abnormalities'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3142055916">
         <span class="h2">
          CML risk score
         </span>
         <span class="headingEndMark">
          —
         </span>
         CML risk score, using one of the validated CML scoring systems  (
         <a class="graphic graphic_table graphicRef60446" href="/z/d/graphic/60446.html" rel="external">
          table 3
         </a>
         ), should be calculated prior to treatment initiation. The preferred scoring system varies by practitioner, but any one of the following is acceptable:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sokal (
         <a class="calc calc_professional" href="/z/d/html/16342.html" rel="external">
          calculator 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Euro (Hasford) [
         <a href="#rid2">
          2
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         EUTOS [
         <a href="#rid3">
          3
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ELTS (EUTOS long-term survival score) (
         <a class="calc calc_professional" href="/z/d/html/127093.html" rel="external">
          calculator 2
         </a>
         ) [
         <a href="#rid4">
          4
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         The Sokal, Hasford, and ELTS scoring systems stratify patients into three risk groups: low, intermediate, and high; EUTOS stratifies patients into low and high-risk groups. ELTS was derived from survival data that reflect treatment of CML with TKIs, and it provides the best discrimination for the probability of CML-specific death [
         <a href="#rid4">
          4,5
         </a>
         ]. The other models were derived from data sets that included some patients who were treated before the routine use of TKIs.
        </p>
        <p>
         Use of clinical scoring systems for defining prognosis in CML is described separately. (See
         <a class="medical medical_review" href="/z/d/html/4543.html" rel="external">
          "Clinical manifestations and diagnosis of chronic myeloid leukemia", section on 'Scoring systems'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1997615458">
         <span class="h1">
          RATIONALE FOR TKI TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         With the exception of CML diagnosed during pregnancy, we recommend a BCR::ABL1 tyrosine kinase inhibitor (TKI) for initial treatment of all patients with CP CML, based on superior treatment outcomes and modest toxicity compared with other treatments (eg, cytotoxic agents, interferons, hematopoietic cell transplantation) [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         All BCR::ABL1 TKIs are associated with similar rates of hematologic, cytogenetic, and molecular remissions and, compared with age- and sex-matched control populations, long-term survival of patients with CP CML is normal or near-normal [
         <a href="#rid7">
          7-11
         </a>
         ]. Selection of a BCR::ABL1 TKI is described below. (See
         <a class="local">
          'Choosing a TKI'
         </a>
         below.)
        </p>
        <p>
         Management of CP CML in pregnancy is discussed below. (See
         <a class="local">
          'Pregnancy'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2390758822">
         <span class="h1">
          CHOOSING A TKI
         </span>
         <span class="headingEndMark">
          —
         </span>
         We stratify selection of a BCR::ABL1 TKI according to the CML risk score and the goal of achieving a treatment-free remission (TFR)  (
         <a class="graphic graphic_algorithm graphicRef130520" href="/z/d/graphic/130520.html" rel="external">
          algorithm 1
         </a>
         ). The choice of a particular TKI for initial treatment must also consider the side effect profile  (
         <a class="graphic graphic_table graphicRef89930" href="/z/d/graphic/89930.html" rel="external">
          table 4
         </a>
         ), comorbid illnesses, availability, cost, and patient preference.
        </p>
        <p>
         Our approach to choosing a BCR::ABL1 TKI for initial treatment of CP CML follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          CML risk score
         </strong>
         – Determination of the CML risk score using one of the validated CML scoring systems  (
         <a class="graphic graphic_table graphicRef60446" href="/z/d/graphic/60446.html" rel="external">
          table 3
         </a>
         ) is described above. (See
         <a class="local">
          'CML risk score'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Selection of a TKI based on CML risk score is described below. (See
         <a class="local">
          'High-risk CML'
         </a>
         below and
         <a class="local">
          'Low- or intermediate-risk CML'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment-free remission
         </strong>
         – For patients who assign a high priority to achieving TFR, selection of a TKI is described below. (See
         <a class="local">
          'TFR is an important goal'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         All BCR::ABL1 TKIs are highly effective for initial treatment of CP CML. There are no significant differences in overall survival (OS) between patients who initiate treatment with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         versus a second-generation (2G) TKI, based on long-term outcomes data from phase 3 trials [
         <a href="#rid12">
          12-15
         </a>
         ]. Compared with imatinib, 2G TKIs generally achieve faster and deeper remissions and are associated with lower rates of progression to advanced phase CML. Details of the efficacy and adverse effects (AEs) of individual TKIs are presented below. (See
         <a class="local">
          'Individual TKIs'
         </a>
         below.)
        </p>
        <p>
         In a meta-analysis of eight randomized trials of TKIs in CP CML,
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         and 2G TKIs achieved comparable rates of OS and progression-free survival (PFS), but 2G TKIs were associated with higher rates of complete cytogenetic response (relative risk [RR] 0.72; 95% CI 0.60-0.85) and major molecular response (ie,
         <em>
          BCR::ABL1
         </em>
         &lt;0.1 percent; RR 0.76; 95% CI 0.63-0.91) [
         <a href="#rid16">
          16
         </a>
         ]. The meta-analysis also reported that disease progression was lower with 2G TKIs than with imatinib (0.8 versus 3.0 percent, respectively; RR 0.35; 95% CI 0.18-0.72). However, this conclusion was strongly influenced by one trial (ENESTnd) among the six that reported rates of disease progression to accelerated phase/blast crisis (AP/BC); methodologic aspects that may have affected the rate of progression in ENESTnd are discussed below [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="local">
          'Nilotinib'
         </a>
         below.)
        </p>
        <p>
         In all randomized trials, approximately one-third of patients switched to alternative TKIs due to toxicity, suboptimal response, or other reasons. Treatment, toxicities, and outcomes with individual TKIs used as initial therapy for CP CML and comparisons of 2G TKIs with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         are presented below. (See
         <a class="local">
          'Individual TKIs'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2991962077">
         <span class="h2">
          High-risk CML
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with high-risk CP CML, we suggest treatment with a 2G TKI (eg,
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         ), when available, rather than
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         (
         <a class="graphic graphic_algorithm graphicRef130520" href="/z/d/graphic/130520.html" rel="external">
          algorithm 1
         </a>
         ). Progression to AP/BC is a concern in patients with high-risk CML and, compared with imatinib, 2G TKIs may be associated with lower rates of disease progression. Nevertheless, imatinib and 2G TKIs achieve comparable rates of OS, PFS, and AEs.
        </p>
        <p>
         None of the 2G TKIs has proven to be superior in this setting. The choice of an individual 2G TKI must consider the toxicity profile, comorbid conditions, availability, cost, and patient preference. Selection of a TKI based on AEs and comorbid conditions is discussed below. (See
         <a class="local">
          'Toxicities'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3864767756">
         <span class="h2">
          Low- or intermediate-risk CML
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with low-risk or intermediate-risk CP CML, the choice of a TKI is influenced by the importance assigned to achievement of a TFR, as described below.
        </p>
        <p class="headingAnchor" id="H2475940811">
         <span class="h3">
          TFR is an important goal
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with low- or intermediate-risk CP CML who consider a TFR an important goal, we suggest a 2G TKI rather than
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         (
         <a class="graphic graphic_algorithm graphicRef130520" href="/z/d/graphic/130520.html" rel="external">
          algorithm 1
         </a>
         ), because 2G TKIs are associated with faster and deeper responses and are more likely to enable a trial of TKI discontinuation. Eligibility criteria for a trial of TKI discontinuation and outcomes are described below. (See
         <a class="local">
          'TKI discontinuation for TFR'
         </a>
         below.)
        </p>
        <p>
         The choice of a TKI must also consider the side effect profile  (
         <a class="graphic graphic_table graphicRef89930" href="/z/d/graphic/89930.html" rel="external">
          table 4
         </a>
         ), comorbid illnesses, availability, cost, and patient preference. (See
         <a class="local">
          'Toxicities'
         </a>
         below.)
        </p>
        <p>
         Approximately half of patients who discontinue a TKI remain in a long-term TFR. A sustained TFR might be expected in 10 to 15 percent of patients with newly diagnosed CML (ie, half of the approximately one-third of patients who achieve a sustained, deep molecular remission). There are no prospective data comparing different TKIs for achievement of TFR, but as a hypothetical example, in the ENESTnd study, among 100 patients who start
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         , 63 would be expected to achieve MR4.5 by five years and half of them (31 patients) would likely have a successful TFR; by contrast, among 100 patients treated with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         , 42 would be expected to achieve MR4 by year 5 and 21 patients would likely achieve a successful TFR [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3943856626">
         <span class="h3">
          TFR is not important
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who do not consider achieving a TFR a high priority, treatment with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         or a 2G TKI is acceptable  (
         <a class="graphic graphic_algorithm graphicRef130520" href="/z/d/graphic/130520.html" rel="external">
          algorithm 1
         </a>
         ). The choice of a TKI must consider the side effect profile  (
         <a class="graphic graphic_table graphicRef89930" href="/z/d/graphic/89930.html" rel="external">
          table 4
         </a>
         ), comorbid illnesses, availability, cost, and patient preference. (See
         <a class="local">
          'Toxicities'
         </a>
         below.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          Imatinib
         </a>
         and 2G TKIs (eg,
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         ) achieve comparable rates of OS, PFS, and AEs [
         <a href="#rid16">
          16
         </a>
         ]. Some clinicians favor imatinib because it has the longest record of safety and efficacy, is most widely available, and is generally least expensive. Others favor 2G TKIs because they generally achieve faster and deeper molecular responses than imatinib. (See
         <a class="local">
          'Individual TKIs'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2736806466">
         <span class="h2">
          Toxicities
         </span>
         <span class="headingEndMark">
          —
         </span>
         All TKIs are associated with certain common AEs (eg, cytopenias, rash, nausea, muscle cramps, edema, diarrhea, fatigue) early in the course of treatment. Most of these early AEs are modest and self-limited or can be managed as discussed below. (See
         <a class="local">
          'Common early toxicities'
         </a>
         below.)
        </p>
        <p>
         Each TKI is also associated with particular AEs, some of which may not be manifest for months or years  (
         <a class="graphic graphic_table graphicRef89930" href="/z/d/graphic/89930.html" rel="external">
          table 4
         </a>
         ). We consider the following to be such defining toxicities:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imatinib
         </strong>
         – Muscle cramps, fatigue, edema, nausea, diarrhea.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nilotinib
         </strong>
         – Coronary, cerebral, and peripheral vascular disease; prolonged QTc interval; hyperglycemia; pancreatitis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dasatinib
         </strong>
         – Pleural effusion, pulmonary hypertension, prolonged QTc interval, platelet dysfunction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Bosutinib
         </strong>
         – Diarrhea, abnormal liver function, rash, pancreatitis.
        </p>
        <p>
        </p>
        <p>
         As examples of how we consider comorbidities and AEs in selecting a TKI  (
         <a class="graphic graphic_algorithm graphicRef130520" href="/z/d/graphic/130520.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with arrhythmias, coronary artery disease, or hyperglycemia, we favor
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         , or
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with a history of pancreatitis we try to avoid
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         and
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with a history of lung disease or at risk for pleural effusion, we favor
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         , or
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         .
        </p>
        <p>
        </p>
        <p>
         In randomized trials of CP CML, approximately one-third of patients switched to alternative TKIs for a variety of reasons, including toxicity and suboptimal response. Treatment, toxicities, and outcomes with individual TKIs used as initial therapy for CP CML and comparisons of 2G TKIs with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         are presented below. (See
         <a class="local">
          'Individual TKIs'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H878980059">
         <span class="h1">
          INDIVIDUAL TKIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several tyrosine kinase inhibitors (TKI) are approved for initial treatment of CP CML [
         <a href="#rid18">
          18
         </a>
         ].
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          Imatinib
         </a>
         was the first commercially available TKI to be approved by the US Food and Drug Administration (FDA) and by the European Medicines Administration (EMA) for initial treatment of CML. Second-generation (2G) TKIs (ie,
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         ) were initially approved for treatment of CML after disease resistance or toxicity with imatinib, but each was subsequently approved by the FDA and EMA for initial treatment of CML based on comparisons with imatinib in randomized trials.
        </p>
        <p class="headingAnchor" id="H2252381855">
         <span class="h2">
          Imatinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          Imatinib
         </a>
         has the longest record of safety and efficacy among TKIs, is available as a generic medication, and is generally less expensive than 2G TKIs. Long-term outcomes with imatinib are comparable to those with 2G TKIs, but imatinib may be slower to achieve cytogenetic and molecular responses [
         <a href="#rid16">
          16
         </a>
         ]. Imatinib is associated with cytopenias and edema, and it causes substantial fluid retention in some patients. We generally avoid imatinib in patients with a history of significant fluid retention or nausea, and we favor 2G TKIs for patients with high-risk CML and for those who assign high priority to achieving a treatment-free remission (TFR), as discussed above. (See
         <a class="local">
          'High-risk CML'
         </a>
         above and
         <a class="local">
          'TFR is an important goal'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial treatment
         </strong>
         – We suggest initial treatment with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         400 mg once daily with a meal and a large glass of water; tablets can also be dispersed in water or apple juice [
         <a href="#rid19">
          19
         </a>
         ]. The initial dose of imatinib should be adjusted for liver or renal impairment, and concurrent use of strong CYP3A4 inducers should be avoided.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxicity
         </strong>
         –
         <strong>
         </strong>
         The most common adverse events (AE) with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         , such as cytopenias, edema, nausea, diarrhea, rash, and muscle cramps  (
         <a class="graphic graphic_table graphicRef89930" href="/z/d/graphic/89930.html" rel="external">
          table 4
         </a>
         ), are generally mild; grade 3 to 4 AEs are reported in ≤5 percent of patients [
         <a href="#rid19">
          19
         </a>
         ]. Imatinib may be associated with hypophosphatemia and decreased bone mineral density [
         <a href="#rid20">
          20,21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The dose should be adjusted for changes in liver and kidney function and the patient should be monitored for fluid retention, particularly in older patients and in those with cardiovascular (CV) comorbidities [
         <a href="#rid19">
          19
         </a>
         ]. Monitoring, dose adjustment, and other management of common early toxicities, cytopenias, and other AEs are discussed below. (See
         <a class="local">
          'Monitoring toxicity'
         </a>
         below and
         <a class="local">
          'Managing toxicity'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes
         </strong>
         – In CP CML,
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         achieves long-term outcomes that are comparable to those with 2G TKIs, but 2G TKIs generally achieve faster and/or deeper cytogenetic and molecular responses [
         <a href="#rid16">
          16
         </a>
         ]. In patients with CP CML, imatinib achieves complete hematologic response (CHR), complete cytogenetic response (CCyR), and major molecular response (MMR; ie, &gt;3-log reduction in
         <em>
          BCR::ABL1
         </em>
         transcripts by the International Scale [IS])  (
         <a class="graphic graphic_table graphicRef90430" href="/z/d/graphic/90430.html" rel="external">
          table 1
         </a>
         ) in &gt;95 percent, &gt;75 percent, and nearly 60 percent, respectively [
         <a href="#rid22">
          22
         </a>
         ]. Definitions of hematologic, cytogenetic, and molecular responses are described below. (See
         <a class="local">
          'Definitions of response'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Phase 3 trials that included
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         as initial treatment of CP CML include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The IRIS (International Randomized Study of Interferon [IFN] and STI571 [
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         ]) trial reported that imatinib is superior to IFN alfa plus
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         [
         <a href="#rid22">
          22
         </a>
         ]. In the IRIS trial, 1106 patients with newly diagnosed CP CML were randomly assigned to imatinib (400 mg once daily) versus IFN alfa (5 million units/m
         <sup>
          2
         </sup>
         daily) plus cytarabine (20 mg/m
         <sup>
          2
         </sup>
         daily for 10 days/month). After 18 months, compared with IFN alfa plus cytarabine, imatinib achieved superior CHR (97 versus 69 percent), CCyR (76 versus 15 percent), MMR (39 versus 2 percent), and progression-free survival (PFS; 97 versus 92 percent). Imatinib was also associated with better quality of life and was better tolerated than IFN alfa plus cytarabine [
         <a href="#rid22">
          22-25
         </a>
         ]. After 10 year follow-up of 204 patients, 93 percent had MMR and 63 percent had MR 4.5 (&gt;4.5-log reduction in
         <em>
          BCR::ABL1
         </em>
         ) [
         <a href="#rid12">
          12
         </a>
         ]. Although 10-year overall survival (OS) in this trial was 84 percent, imatinib did not achieve a survival advantage because approximately 90 percent of patients assigned to receive IFN alfa plus cytarabine ultimately crossed over to imatinib [
         <a href="#rid12">
          12,26-28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The CML-IV trial evaluated various
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         doses and combinations with other agents [
         <a href="#rid8">
          8
         </a>
         ]. In CML-IV, 1551 patients were randomly assigned to imatinib 400 mg per day, imatinib 800 mg per day, or imatinib 400 mg daily plus either IFN alfa or
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         . After 10 years, PFS and OS were 80 and 82 percent, respectively, and there were no survival differences among treatment arms. Other studies of imatinib in CP CML reported similar clinical outcomes and toxicities [
         <a href="#rid29">
          29-40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Higher doses of
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         (eg, 600 mg, 800 mg) or a combination of imatinib with other agents (eg,
         <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">
          cytarabine
         </a>
         , interferon alfa) can achieve earlier cytogenetic and molecular milestones, but higher doses are associated with more toxicity and do not improve OS [
         <a href="#rid8">
          8,41-49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Prospective trials that compared
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         to 2G TKIs in CP CML are described below. (See
         <a class="local">
          'Nilotinib'
         </a>
         below and
         <a class="local">
          'Dasatinib'
         </a>
         below and
         <a class="local">
          'Bosutinib'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1123582902">
         <span class="h2">
          Second-generation (2G) TKIs
         </span>
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Nilotinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          Nilotinib
         </a>
         is a 2G TKI and it is the only TKI that must be taken twice daily and without food. Nilotinib is associated with cytopenias, hepatotoxicity, QTc prolongation, pancreatitis, and long-term CV complications  (
         <a class="graphic graphic_table graphicRef89930" href="/z/d/graphic/89930.html" rel="external">
          table 4
         </a>
         ). As discussed below, nilotinib may be associated with lower rates of progression to accelerated phase (AP) or blast crisis (BC) than
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         .
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial treatment
         </strong>
         – We suggest initial treatment with
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         300 mg twice daily (approximately 12 hours apart) with water; patients should avoid food ≥2 hours before and ≥1 hour after taking each dose [
         <a href="#rid50">
          50
         </a>
         ]. Lipase and amylase should be tested prior to treatment. Patients should be screened by electrocardiogram (EKG) for QTc interval at baseline, potassium and magnesium levels should be corrected, and other medications that may prolong QTc interval  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 5
         </a>
         ) should be avoided. Caution is advised for patients with poorly controlled diabetes, liver disease, pancreatitis, or substantial CV risk factors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxicity
         </strong>
         – Most AEs  (
         <a class="graphic graphic_table graphicRef89930" href="/z/d/graphic/89930.html" rel="external">
          table 4
         </a>
         ) are mild and self-limited, but pancreatitis and a low incidence of sudden deaths (which may be related to ventricular repolarization abnormalities) have been reported [
         <a href="#rid50">
          50
         </a>
         ]. Later effects of
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         therapy include occlusive cardiac, cerebral, and peripheral artery disease; liver disease; and hyperglycemia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The dose of
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         should be adjusted for prolongation of QTc interval, elevation of lipase/amylase, or changes in liver and kidney function [
         <a href="#rid50">
          50
         </a>
         ]. Monitoring, dose adjustment, and other management for common early toxicities, cytopenias, changes in lipase/amylase and liver function tests, prolongation of QTc interval, and other cardiovascular events are discussed below. (See
         <a class="local">
          'Monitoring toxicity'
         </a>
         below and
         <a class="local">
          'Managing toxicity'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes
         </strong>
         – Treatment with
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         300 mg twice daily, when directly compared with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         , was associated with comparable PFS and OS (approximately 95 percent OS after two years), higher rates of molecular responses, more CV events, and lower rates of progression to AP/BC in one study (ENESTnd).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The following trials directly compared
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In ENESTnd, 846 previously untreated patients with CP CML were randomly assigned to
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         300 mg twice daily, nilotinib 400 mg twice daily, or
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         400 mg daily [
         <a href="#rid13">
          13,51-54
         </a>
         ]. Compared with imatinib, nilotinib 300 mg twice daily (the approved dose) was associated with comparable five-year OS, PFS, and event-free survival (EFS). The estimated rate of progression to AP/BC at five years was lower with nilotinib than imatinib. Compared with imatinib (33 patients progressed to AP/BC), progression was reported in 12 patients taking nilotinib 300 mg twice daily (HR 0.46; 95% CI 0.22-0.99) and 9 patients taking nilotinib 400 mg twice daily (HR 0.28; 95% CI 0.11-0.68) [
         <a href="#rid13">
          13
         </a>
         ]. Most progression events occurred in patients with intermediate- or high-risk disease. Nilotinib 400 mg twice daily was superior to imatinib with regard to OS, PFS, EFS, and progression, but this dose was associated with unacceptable levels of CV toxicity [
         <a href="#rid13">
          13,51-54
         </a>
         ]. More than half of all patients treated with nilotinib (at either dose level) achieved MR 4.5, compared with less than one-third with imatinib.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In ENESTnd, the incidence of grade ≥3 AEs and toxicity that led to treatment discontinuation were comparable between
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         300 mg twice daily and
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         [
         <a href="#rid13">
          13
         </a>
         ]. Compared with imatinib, both dose levels of nilotinib were associated with less fluid retention, pleural effusion, pericardial effusion, pulmonary edema, and grade ≥3 neutropenia. However, all-grade CV events (eg, ischemic heart disease, ischemic CV events, peripheral artery disease) were reported in 7.5 percent, 13.4 percent, and 2.1 percent of patients in the nilotinib 300 mg, nilotinib 400 mg, and imatinib arms, respectively. With five years of follow-up, new or worsening grade ≥3 elevations of lipase, glucose, and liver enzymes were more common in either nilotinib arm than with imatinib. Grade ≥3 symptomatic prolongation of QTc was reported in 0.7 and 1.4 percent of patients treated with nilotinib 300 mg or 400 mg.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In ENESTchina, 267 Chinese patients with newly diagnosed CP CML were randomly assigned to
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         (300 mg twice daily) versus
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         (400 mg daily) [
         <a href="#rid55">
          55
         </a>
         ]. Nilotinib achieved higher MMR at 12 months (52 versus 28 percent) and similar rates of both CCyR (84 versus 87 percent) and freedom from progression (95 percent each) at 24 months [
         <a href="#rid55">
          55
         </a>
         ]. Toxicities were similar to those reported in ENESTnd.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h3">
          Dasatinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          Dasatinib
         </a>
         is a 2G TKI that is associated with cytopenias, pleural effusions, other fluid retention, QT prolongation, and bleeding  (
         <a class="graphic graphic_table graphicRef89930" href="/z/d/graphic/89930.html" rel="external">
          table 4
         </a>
         ). It should not be given to patients with hypokalemia, hypomagnesemia, or who have or may develop prolongation of the QTc interval, and we generally avoid dasatinib in patients with a bleeding history, pleural effusion, and heart failure. Caution is advised when it is given with certain medications (described below).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial treatment
         </strong>
         – We suggest initial treatment with
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         100 mg once daily, with or without a meal; tablets should not be crushed or cut [
         <a href="#rid56">
          56
         </a>
         ]. Patients should be screened by EKG for QTc interval at baseline, and hypokalemia or hypomagnesemia should be corrected before administration of dasatinib. No initial dose adjustment is required for patients with liver or kidney impairment, but caution is advised in patients who require anticoagulants, medications that inhibit platelet function, anti-arrhythmic medicines or other products that may lead to QTc prolongation  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 5
         </a>
         ), strong CYP3A4 inducers or inhibitors  (
         <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">
          table 6
         </a>
         ), St. John's wort, antacids, H2 antihistamines, and proton pump inhibitors (PPIs).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxicity
         </strong>
         – Most AEs  (
         <a class="graphic graphic_table graphicRef89930" href="/z/d/graphic/89930.html" rel="external">
          table 4
         </a>
         ) are mild and self-limited. However, patients may experience QTc prolongation, fluid retention (grade ≥3 in approximately 4 percent), exacerbation of congestive heart failure, or significant bleeding [
         <a href="#rid56">
          56
         </a>
         ]. Severe and potentially fatal central nervous system (CNS) and gastrointestinal hemorrhages have been reported in approximately 1 and 4 percent of patients, respectively; most bleeding events were associated with severe thrombocytopenia, anticoagulants, and/or inhibitors of platelet function.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The dose of
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         should be adjusted for prolongation of QTc interval. Patients who develop dyspnea, dry cough, or other findings suggestive of pleural effusion should be evaluated with a chest radiograph; some patients develop a patchy interstitial pneumonitis with fever that can mimic an infection and rare cases of pulmonary hypertension have been reported. Lymphocytosis (likely representing T/NK cells) that persisted for &gt;12 months occurred in one-third of patients treated with dasatinib and these patients were more likely to have pleural effusions and favorable cytogenetic and molecular responses [
         <a href="#rid57">
          57
         </a>
         ]. Monitoring, dose adjustment, and other management for common early toxicities, cytopenias, prolongation of QTc interval, other cardiovascular events, bleeding/bruising, and pleural effusion are discussed below. (See
         <a class="local">
          'Monitoring toxicity'
         </a>
         below and
         <a class="local">
          'Managing toxicity'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes
         </strong>
         –
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          Dasatinib
         </a>
         achieved 97 percent OS and 93 percent PFS at three years, and MMR in more than three-quarters of patients with CP CML [
         <a href="#rid58">
          58
         </a>
         ]. The following trials directly compared dasatinib with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The DASISION trial randomly assigned 519 patients with previously untreated CML to
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         100 mg daily versus
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         400 mg daily [
         <a href="#rid14">
          14,59-61
         </a>
         ]. At five-year follow-up, compared with imatinib, dasatinib did not achieve superior PFS or OS, but 26 percent of patients initially treated with imatinib were subsequently treated with a 2G TKI. Dasatinib generally produced faster and deeper molecular responses, with MR at three months (84 versus 64 percent) and MMR 4.5 (42 versus 33 percent). After five years, progression to AP/BC occurred in 4.6 and 7.3 percent of patients treated with dasatinib and imatinib, respectively [
         <a href="#rid14">
          14
         </a>
         ]. AEs led to discontinuation of therapy in 16 and 7 percent of patients treated with dasatinib and imatinib, respectively [
         <a href="#rid14">
          14
         </a>
         ]. Except for pleural effusion (28 versus 1 percent), nonhematologic AEs (eg, nausea, vomiting, rash, myalgia) and hematologic AEs were less common with dasatinib than with imatinib.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Similar results were noted in a randomized phase 2 study of
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         (100 mg daily) versus
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         (400 mg daily) in 246 patients with newly diagnosed CP CML [
         <a href="#rid58">
          58
         </a>
         ]. After three years, dasatinib and imatinib achieved similar estimated rates of OS (97 percent each), PFS (93 versus 90 percent, respectively), and relapse-free survival (91 versus 88 percent), but dasatinib resulted in higher rates of CCyR (84 versus 69 percent) and MMR at 12 months (59 versus 44 percent). Pleural effusions, headache, and diarrhea were more common with dasatinib, while edema, nausea, and muscle pain were more common with imatinib.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A lower starting dose of
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         may be effective, but we await long-term outcomes before suggesting its use outside of a clinical trial. In a phase 2 study, 81 patients with newly diagnosed CP CML were treated with dasatinib 50 mg daily; with &gt;12 month follow-up, CCyR was achieved by 77 and 95 percent by 6 and 12 months, respectively [
         <a href="#rid62">
          62
         </a>
         ]. At 12 months, cumulative MMR rate was 81 percent and MR4.0 and MR4.5 rates were 55 and 49 percent, respectively. The 50 mg daily dose was well tolerated, with pleural effusion in 6 percent.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2439941783">
         <span class="h3">
          Bosutinib
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          Bosutinib
         </a>
         is a 2G TKI that is associated with cytopenias, diarrhea, abnormal liver function, and fluid retention. We generally avoid use of bosutinib in patients with liver or kidney dysfunction, diarrhea, and heart failure, and caution is advised when it is given with certain medications.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial treatment
         </strong>
         – For initial therapy of CP CML, the FDA-approved dose is 400 mg once daily [
         <a href="#rid63">
          63
         </a>
         ]; this dose is better tolerated than 500 mg daily used in some studies (described below). Some clinicians begin with
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         100 mg once daily and escalate the dose by 100 mg every week until reaching 400 mg daily, to reduce diarrhea or liver toxicity [
         <a href="#rid64">
          64
         </a>
         ]. The daily dose should be reduced for patients with liver or kidney disease or those taking CYP3A4 inducers or inhibitors  (
         <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">
          table 6
         </a>
         ) and PPIs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxicity
         </strong>
         – Most AEs  (
         <a class="graphic graphic_table graphicRef89930" href="/z/d/graphic/89930.html" rel="external">
          table 4
         </a>
         ) are mild and self-limited. However, diarrhea, nausea, and abdominal pain occur commonly, and grade ≥3 diarrhea or abnormal liver function tests are each reported in approximately 8 percent, with most such toxicities occurring during the first one to two months of treatment and resolving thereafter [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          Bosutinib
         </a>
         should be temporarily held or the dose adjusted for significant gastrointestinal toxicity [
         <a href="#rid63">
          63
         </a>
         ]. Monitoring, dose adjustment, and other management for common early toxicities, cytopenias, and gastrointestinal AEs are discussed below. (See
         <a class="local">
          'Monitoring toxicity'
         </a>
         below and
         <a class="local">
          'Managing toxicity'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Outcomes
         </strong>
         –
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          Bosutinib
         </a>
         can achieve rates of cytogenetic and molecular responses that are comparable to other 2G TKIs and
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         [
         <a href="#rid16">
          16
         </a>
         ]. The following randomized trials directly compared bosutinib versus imatinib in newly diagnosed CP CML:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The BELA trial randomly assigned 502 patients to
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         (500 mg daily) versus
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         (400 mg daily) [
         <a href="#rid65">
          65,66
         </a>
         ]. Bosutinib achieved faster cytogenetic responses, but compared with imatinib, similar rates of CCyR and MMR after ≥24-month follow-up. Bosutinib was associated with a lower rate of a composite outcome of disease progression/lack of efficacy (3 versus 10 percent, respectively), and responses to bosutinib did not differ based on Sokal score. Bosutinib was associated with more diarrhea and elevations of liver function tests and a higher rate of drug discontinuation due to adverse events (19 versus 6 percent) [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The BFORE trial randomly assigned 536 adults to
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         (400 mg once daily) versus
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         (400 mg once daily) [
         <a href="#rid15">
          15
         </a>
         ]. Bosutinib achieved higher rates of MMR (47 versus 37 percent, respectively) and CCyR (77 versus 66 percent) at 12 months and reached these milestones more quickly. Any type of grade ≥3 toxicity occurred in 56 percent of patients receiving bosutinib and 43 percent of patients receiving imatinib; treatment was discontinued by 22 percent of patients receiving bosutinib and 27 percent of patients receiving imatinib. Bosutinib was associated with more grade ≥3 diarrhea (8 versus 1 percent, respectively) and elevated serum transaminases, but cardiac and vascular toxicities were uncommon with both treatments.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3774109427">
         <span class="h2">
          Other TKIs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other TKIs have been approved for treatment of CML in specific clinical settings or countries:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Radotinib
         </strong>
         – Radotinib is a 2G TKI approved by the Korea Food and Drug Administration (KFDA) for initial treatment of CML or CML that is refractory to other TKIs. Compared with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         , radotinib achieved faster cytogenetic and molecular responses in the RERISE study, which randomly assigned 241 patients with previously untreated CML to radotinib (either 300 or 400 mg twice daily) versus imatinib (400 mg once daily) [
         <a href="#rid67">
          67
         </a>
         ]. Compared with imatinib, radotinib achieved superior MMR and CCyR at 12 months, and early molecular response at three months. Responses were similar with both doses of radotinib.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Flumatinib
         </strong>
         – Flumatinib
         <strong>
         </strong>
         is a 2G TKI available in China. In one trial, 394 patients with CP CML were randomly assigned to flumatinib (600 mg once daily) versus
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         (400 mg once daily) [
         <a href="#rid68">
          68
         </a>
         ]. At 12 months, compared with patients receiving imatinib, more patients receiving flumatinib achieved MR4 (23 versus 12 percent) and no patients progressed to AP/BC (versus four patients taking imatinib). This trial differed from other large phase 3 studies of 2G TKIs because only 7 percent of patients had high-risk CML.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ponatinib
         </strong>
         –
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          Ponatinib
         </a>
         is a third-generation TKI that is approved for treatment of CML that is resistant or patients who are intolerant of prior TKIs, as discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4515.html" rel="external">
          "Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy", section on 'Ponatinib'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3626332334">
         <span class="h1">
          TREATMENT RESPONSE
         </span>
        </p>
        <p class="headingAnchor" id="H2841341896">
         <span class="h2">
          Response monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Response to treatment with a tyrosine kinase inhibitor (TKI) is evaluated by the timely achievement of hematologic, cytogenetic, and molecular milestones  (
         <a class="graphic graphic_table graphicRef90418" href="/z/d/graphic/90418.html" rel="external">
          table 7
         </a>
         ). (See
         <a class="local">
          'Definitions of response'
         </a>
         below.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Achievement of milestones
         </strong>
         – For patients who achieve treatment milestones on schedule, sustain the response, and have acceptable levels of toxicity, treatment should continue indefinitely.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For certain patients, a trial of TKI discontinuation or de-escalation may be considered. (See
         <a class="local">
          'TKI discontinuation for TFR'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Failure to achieve milestones
         </strong>
         – All patients who fail to achieve treatment response milestones  (
         <a class="graphic graphic_table graphicRef90418" href="/z/d/graphic/90418.html" rel="external">
          table 7
         </a>
         ) should be evaluated for adherence to treatment and possible drug interactions. Evidence of loss of response should be confirmed with repeat studies before treatment changes are initiated.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Management of CML that is resistant to TKI therapy is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4515.html" rel="external">
          "Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Serial measurement in peripheral blood of
         <em>
          BCR::ABL1
         </em>
         by quantitative polymerase chain reaction (qPCR) is the preferred method for monitoring treatment response; the qPCR assay should be standardized and have a sensitivity of ≥4.5-log reduction from the baseline, as described below. (See
         <a class="local">
          'Definitions of response'
         </a>
         below.)
        </p>
        <p>
         Optimal responses are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         3 months:
         <em>
          BCR::ABL1
         </em>
         (International Scale [IS]) ≤10 percent and/or ≤35 percent Philadelphia chromosome-positive (Ph+) metaphase cells
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         6 months:
         <em>
          BCR::ABL1
         </em>
         (IS) ≤1 percent and/or 0 percent Ph+ cells
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         12 months:
         <em>
          BCR::ABL1
         </em>
         (IS) ≤0.1 percent
        </p>
        <p>
        </p>
        <p>
         After
         <em>
          BCR::ABL1
         </em>
         is ≤0.1 percent, it should be measured every three months for the first two years and then every three to six months thereafter. At very low levels, the level of transcripts can fluctuate several-fold with successive tests. However, if there is a 1-log increase in
         <em>
          BCR::ABL1
         </em>
         after achieving MMR (ie, MR3), this should be confirmed by repeating qPCR in one to three months.
        </p>
        <p>
         Measurement of molecular response by qPCR has greater sensitivity than cytogenetic assays, and qPCR is the only tool that can monitor responses after a patient has achieved a complete cytogenetic response (CCyR).
        </p>
        <p>
         It is not necessary to serially assess bone marrow for cytogenetic or molecular response. We generally reserve additional bone marrow biopsies for patients exhibiting resistance to a TKI, progression of CML, development of dysplasia or cytopenias. However, for patients who have additional cytogenetic abnormalities that are detected in Philadelphia chromosome (Ph)-negative cells, it may be necessary to monitor progression of that clone with serial cytogenetic studies, as described below. (See
         <a class="local">
          'Additional chromosomal abnormalities'
         </a>
         below.)
        </p>
        <p>
         Our approach to monitoring disease in patients in chronic phase is consistent with those proposed by the European LeukemiaNet  (
         <a class="graphic graphic_table graphicRef90430" href="/z/d/graphic/90430.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_algorithm graphicRef95904" href="/z/d/graphic/95904.html" rel="external">
          algorithm 2
         </a>
         ) [
         <a href="#rid69">
          69
         </a>
         ] and National Cancer Center Network (NCCN) [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4035741600">
         <span class="h2">
          Definitions of response
         </span>
        </p>
        <p class="headingAnchor" id="H2800401910">
         <span class="h3">
          Clinical and cytogenetic responses
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hematologic response
         </strong>
         – Hematologic response is assessed by the white blood cell (WBC) count, differential, platelet count, and improvement in splenomegaly [
         <a href="#rid69">
          69,71
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Complete hematologic response (CHR)
         </strong>
         is defined by normalization of all peripheral blood counts, WBC count &lt;10,000/microL, platelet count &lt;450,000/microL, no circulating immature myeloid cells (eg, blasts, promyelocytes, myelocytes), and no clinical findings of disease, including disappearance of a palpable spleen [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cytogenetic response
         </strong>
         – Cytogenetic response is assessed by chromosome banding of ≥20 bone marrow cell metaphases:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Complete cytogenetic response (CCyR)
         </strong>
         : No Ph+ metaphases detected
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Major cytogenetic response
         </strong>
         : 0 to 35 percent Ph+ metaphases
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Minor cytogenetic response
         </strong>
         :
         <strong>
         </strong>
         &gt;35 percent Ph+ metaphases
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We consider that fluorescence in situ hybridization (FISH) is not a preferred method for monitoring cytogenetic response, because it will not detect the emergence of additional chromosomal abnormalities, and the risk of false positive or false negative findings given the limited number of cells that are typically analyzed by interphase FISH [
         <a href="#rid73">
          73
         </a>
         ]. Although FISH &lt;1 percent generally corresponds to CCyR, endpoints for cytogenetic response with FISH have not been defined [
         <a href="#rid74">
          74,75
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4048235540">
         <span class="h3">
          Molecular response
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Molecular response
         </strong>
         – Molecular response is assessed by qPCR of
         <em>
          BCR::ABL1
         </em>
         , which compares the level of
         <em>
          BCR::ABL1
         </em>
         transcripts to other control genes (eg,
         <em>
          BCR, ABL1,
         </em>
         or
         <em>
          GUSB
         </em>
         ) [
         <a href="#rid24">
          24,76
         </a>
         ]. The results should be expressed using the IS, which assumes a standardized baseline value of 100 percent for all patients and should have a sensitivity of ≥4.5-log. Molecular response can be described as:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Early molecular response (EMR)
         </strong>
         :
         <em>
          BCR::ABL1
         </em>
         ≤10 percent at three and/or six months.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Major molecular response (MMR)
         </strong>
         :
         <em>
          BCR::ABL1
         </em>
         ≤0.1 percent.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Undetectable
         </strong>
         <strong>
          <em>
           BCR::ABL1
          </em>
         </strong>
         : The level of sensitivity of the assay should be provided in the report (eg, MR4, MR4.5). To illustrate this concept, a value of MR4 corresponds to detection of one CML cell among 10,000 (ie, 10
         <sup>
          4
         </sup>
         ) normal cells.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Molecular response can also be described by the log reduction below the standard 100 percent baseline value of the IS:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          MR2
         </strong>
         –
         <em>
          BCR::ABL1
         </em>
         ≤1 percent (ie, ≥2 log reduction from the standardized baseline); this level roughly corresponds to CCyR.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          MR3
         </strong>
         –
         <em>
          BCR::ABL1
         </em>
         ≤0.1 percent (ie, ≥3 log reduction); MR3 is equivalent to MMR.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          MR4
         </strong>
         –
         <em>
          BCR::ABL1
         </em>
         ≤0.01 percent (ie, ≥4 log reduction).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          MR4.5
         </strong>
         –
         <em>
          BCR::ABL1
         </em>
         ≤0.0032 percent (ie, ≥4.5 log reduction); this is the current limit of most commercially available assays.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2917733968">
         <span class="h1">
          MONITORING TOXICITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach for monitoring toxicity of all tyrosine kinase inhibitors (TKI) includes history, physical examination, laboratory studies, and specialized evaluations, as needed. For adverse events (AE) that are more common or severe with specific TKIs, additional monitoring is suggested above. (See
         <a class="local">
          'Individual TKIs'
         </a>
         above.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          History and physical examination
         </strong>
         – History should include assessment of common early toxicities that may occur with all TKIs, including nausea, muscle cramps, rash, edema, fatigue, and diarrhea.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A complete list of medications should be reviewed for potential interactions with TKIs. For patients taking
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         or
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         it is particularly important to consider medications that may prolong the QTc interval  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 5
         </a>
         ) and inhibitors or inducers of cytochrome P450 3A  (
         <a class="graphic graphic_table graphicRef76992" href="/z/d/graphic/76992.html" rel="external">
          table 6
         </a>
         ) and review of cardiovascular risk factors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Review of systems should elicit a history of bleeding or bruising; chest pain, shortness of breath, palpitations, claudication, or other symptoms that may indicate cardiovascular complications; cough or dyspnea that may suggest pleural effusion, pulmonary hypertension, or interstitial lung disease; jaundice, abdominal pain, persistent nausea/vomiting, bleeding, or other findings that suggest liver disease, pancreatitis, or gastrointestinal bleeding.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Physical examination should focus on the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Imatinib
         </strong>
         – Peripheral and periorbital edema and rash.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Nilotinib
         </strong>
         – Jaundice, hepatomegaly, abdominal tenderness that may suggest liver disease or pancreatitis; pallor or reduced pulses of extremities, carotid bruit, cardiac dysrhythmia, edema that may suggest cardiovascular disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Dasatinib
         </strong>
         – Chest auscultation and cardiac exam, bleeding/bruising; edema, cardiac dysrhythmia, fluid retention, tachypnea, or other findings consistent with cardiovascular disease or pleural effusion.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Bosutinib
         </strong>
         – Abdominal pain, jaundice, or other findings associated with liver disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complete blood count
         </strong>
         (CBC) with differential count every two weeks for the first two months of TKI therapy, monthly for the next six months, and then as needed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Serum chemistries
         </strong>
         should include renal, liver function tests, and uric acid every two weeks for the first two months, then as clinically indicated. In addition, we suggest the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Potassium, phosphate, and magnesium for patients taking
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         and
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lipase and amylase in the first several months of treatment for patients taking
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         , and
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other testing
         </strong>
         – We do not suggest routine imaging or other studies, unless it is suggested for the specific TKI. Examples include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Electrocardiograms (EKG) to evaluate the QTc interval for patients taking
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         or
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chest radiograph for patients with a cough or dyspnea who are taking
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         .
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1611318802">
         <span class="h1">
          MANAGING TOXICITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Management of toxicity is crucial for long-term adherence to a tyrosine kinase inhibitor (TKI) regimen. Most patients with CML will require TKI therapy for the remainder of life, so maintaining treatment adherence requires effective management of both short-term and long-term toxicity. Persistent low-grade toxicities can adversely affect quality of life (QoL) and are barriers to long-term treatment adherence. Clinicians may underestimate the impact of grade 1 to 2 adverse events (AE), so the importance of reporting AEs should be emphasized at the initiation of TKI therapy and repeatedly during treatment.
        </p>
        <p class="headingAnchor" id="H309518038">
         <span class="h2">
          Key principles
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the first months of therapy, all TKIs are associated with certain common early toxicities (eg, rash, nausea, fatigue, edema, fatigue, myalgias/arthralgias). However, each TKI also has certain distinctive short-term or long-term toxicities  (
         <a class="graphic graphic_table graphicRef89930" href="/z/d/graphic/89930.html" rel="external">
          table 4
         </a>
         ). (See
         <a class="local">
          'Choosing a TKI'
         </a>
         above and
         <a class="local">
          'Individual TKIs'
         </a>
         above.)
        </p>
        <p>
         TKI-associated AEs typically:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Arise in the first year of treatment, although some (eg, cardiovascular AEs with
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         or
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         ) may not emerge for many months or years.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Are mostly mild to moderate in intensity (ie, grade ≤2).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Resolve spontaneously or can be controlled by dose adjustments.
        </p>
        <p>
        </p>
        <p>
         We attempt to ameliorate AEs with symptomatic management, avoidance of medications that may exacerbate the toxicity, and judicious TKI dose adjustment or brief interruption. However, dose reductions should be undertaken with careful monitoring of molecular response to avoid administering a subtherapeutic dose. Extended interruptions of TKI treatment should be avoided because they may affect disease outcomes.
        </p>
        <p>
         Once a deep molecular response is achieved, it may be possible to reduce the dose or temporarily discontinue the TKI to ameliorate low-grade AEs and/or lessen long-term complications, while still maintaining the remission. In a multicenter study, remission was sustained after 12 months of half-dose TKI therapy (ie,
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         200 mg daily,
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         50 mg daily, or
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         200 mg twice daily) in 162 of 174 patients (93 percent) patients who had taken a TKI for ≥3 years and achieved at least major molecular response (MMR; ie, &lt;0.1 percent
         <em>
          BCR::ABL1
         </em>
         ratio) for ≥12 months [
         <a href="#rid77">
          77
         </a>
         ]. The rate of recurrence was unrelated to the specific TKI or duration of TKI therapy but was lower in patients who entered the study with MR4 (2 percent recurrence) than in those with MR3 (19 percent); remission was regained within four months of full dose therapy in all patients. Importantly, AEs (eg, lethargy, diarrhea, rash, nausea) improved during the three months of de-escalation, but not thereafter.
        </p>
        <p>
         For severe, intractable TKI-associated toxicity, a change to an alternative TKI is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4515.html" rel="external">
          "Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy"
         </a>
         .)
        </p>
        <p>
         TKI-associated AEs affect treatment adherence [
         <a href="#rid78">
          78
         </a>
         ] and poor adherence to treatment may worsen clinical outcomes. A study that electronically monitored
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         adherence in 87 patients with stable complete cytogenetic response reported that treatment adherence was an independent predictor of MMR; patients with ≥90 percent adherence had a significantly higher rate of MMR at six years (95 versus 28 percent), whereas no patient who took ≤80 percent of the prescribed dose attained a MMR [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
         TKI-associated AEs impair the QoL in patients with CML. A survey-based study of 448 patients with CML treated with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         for a median of five years reported that patients &gt;60 years old had health-related QoL (HRQoL) scores similar to an age-matched general population, but younger patients reported significantly worse HRQoL than controls [
         <a href="#rid80">
          80
         </a>
         ]. Other studies reported that one-third to one-half of patients taking TKIs experienced symptoms that affected mood, general well-being, enjoyment of life, or interfered with daily functioning [
         <a href="#rid81">
          81,82
         </a>
         ]. Randomized trials have reported no difference in QoL between patients taking imatinib and either
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         or
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         [
         <a href="#rid83">
          83,84
         </a>
         ]. (See
         <a class="local">
          'Nilotinib'
         </a>
         above and
         <a class="local">
          'Dasatinib'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1647622650">
         <span class="h2">
          Common early toxicities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain AEs, including nausea, muscle cramps, rash, and edema, can occur with all TKIs in the first months of therapy, although some are more common or severe with particular TKIs  (
         <a class="graphic graphic_table graphicRef89930" href="/z/d/graphic/89930.html" rel="external">
          table 4
         </a>
         ). Most early toxicities can be managed with symptomatic care, avoidance of medications that may exacerbate the toxicity, and temporarily reducing or holding the TKI.
        </p>
        <p>
         Common early AEs include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nausea
         </strong>
         – Mild nausea is common early in the course of treatment with all TKIs, but it is generally most severe or persistent with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         and
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         ; the incidence of nausea is decreased when these TKIs are taken with food. It is important to emphasize that
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         should
         <strong>
          not
         </strong>
         be taken with food. If the patient experiences persistent, severe TKI-associated nausea and/or vomiting, a trial of antiemetics may be beneficial. (See
         <a class="medical medical_review" href="/z/d/html/2537.html" rel="external">
          "Approach to the adult with nausea and vomiting", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Muscle cramps
         </strong>
         – All TKIs can cause muscle cramps, which most often affect the calves, feet, and hands. Mild cramps are most common with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         (approximately half of patients), but can be more severe (grade ≥3) in approximately 2 percent of patients [
         <a href="#rid19">
          19
         </a>
         ]. There is no universally effective treatment for cramps, but electrolyte abnormalities should be corrected. Anecdotally, some patients benefit from calcium or magnesium supplements. Other symptomatic management is described separately. (See
         <a class="medical medical_review" href="/z/d/html/5177.html" rel="external">
          "Nocturnal leg cramps", section on 'Management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Rash
         </strong>
         – A mild, maculopapular rash occurs in up to one-half of patients treated with TKIs, which generally resolves with continued treatment [
         <a href="#rid85">
          85-88
         </a>
         ]. Management of more persistent or troublesome rash is described separately. (See
         <a class="medical medical_review" href="/z/d/html/15762.html" rel="external">
          "Exanthematous (maculopapular) drug eruption", section on 'Management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Edema
         </strong>
         – Fluid retention can typically be managed by symptomatic care (eg, leg elevation, judicious use of diuretics). Periorbital edema is common with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         and does not respond to diuretic therapy. Liver, kidney, and/or cardiac function should be evaluated for more severe fluid retention, pleuro-pericardial effusion, or ascites. (See
         <a class="medical medical_review" href="/z/d/html/3510.html" rel="external">
          "Heart failure: Clinical manifestations and diagnosis in adults", section on 'Initial testing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diarrhea
         </strong>
         – Diarrhea is most common with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         and
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         but generally resolves within weeks. Treatment with antidiarrheal agents (eg,
         <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">
          loperamide
         </a>
         ) or temporary dose reductions maybe necessary to control diarrhea in some patients. It is important to question patients about possible lactose intolerance, which can exacerbate TKI induced diarrhea.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Fatigue
         </strong>
         – Fatigue is a common symptom associated with TKI therapy. There are no specific remedies to TKI-associated fatigue. Careful dose reductions when patients achieve a deep molecular response may be useful for lessening symptomatic fatigue. Other causes of fatigue (eg, hypothyroidism, sleep disturbance) should be considered as contributing factors.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2728096038">
         <span class="h2">
          Hematologic
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cytopenias
         </strong>
         – Mild to moderate cytopenias are common early in the course of treatment with all TKIs [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Early, mild TKI-associated cytopenias may be an anticipated, "on-target" effect that reflects the mechanism of action, rather than an allergic or adverse effect of TKIs [
         <a href="#rid34">
          34
         </a>
         ]. At the time of diagnosis, circulating blood cells are dominated by progeny of the Ph+ clone, which are effectively eliminated by the TKI. Early cytopenias appear to reflect the slow recovery of normal, Ph-negative hematopoiesis; as a consequence, discontinuing or reducing the dose of the TKI may not solve the problem.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For most patients, the TKI can be continued with the expectation of improvement in blood counts over time as normal hematopoiesis recovers.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a minority of patients, severe or symptomatic cytopenias (eg, infection, bleeding) may require a dose reduction or temporary discontinuation of the TKI. This is usually followed by a gradual improvement in counts that permits restoration of the TKI dose but, occasionally, longer-term treatment with a lower dose of the TKI is needed to maintain adequate blood counts.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Rarely, critical cytopenias develop:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Neutropenia or thrombocytopenia – For persistent, severe neutropenia or thrombocytopenia, treatment with growth factors to stimulate recovery of normal hematopoiesis is safe and usually effective. Myeloid growth factors can ameliorate severe neutropenia, but there is less experience with platelet stimulating agents for severe thrombocytopenia. If hematopoietic growth factors are used to support normal hematopoiesis, an effort should be made to continue the TKI to prevent regrowth of the CML clone. (See
         <a class="medical medical_review" href="/z/d/html/16889.html" rel="external">
          "Use of granulocyte colony stimulating factors in adult patients with chemotherapy-induced neutropenia and conditions other than acute leukemia, myelodysplastic syndrome, and hematopoietic cell transplantation", section on 'Granulocyte colony stimulating factors'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6671.html" rel="external">
          "Clinical applications of thrombopoietic growth factors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Anemia – For patients with persistent symptomatic anemia, we check the reticulocyte count, ferritin, iron saturation, vitamin B12, and folate and correct any nutritional deficiencies detected. Transfusion support may be used if symptomatic. (See
         <a class="medical medical_review" href="/z/d/html/7948.html" rel="external">
          "Indications and hemoglobin thresholds for RBC transfusion in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         We suggest
         <strong>
          not
         </strong>
         treating TKI-associated anemia in CML with erythropoiesis-stimulating agents (ESA), because such treatment was associated with a higher rate of thrombosis in patients with CP CML and did not improve rates of survival or cytogenetic response [
         <a href="#rid90">
          90
         </a>
         ]. The US Centers for Medicare and Medicaid Services (CMS) and the US Food and Drug Administration do not support the use of ESAs in patients with CML. (See
         <a class="medical medical_review" href="/z/d/html/2799.html" rel="external">
          "Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Should critical cytopenias persist, a switch to a different TKI can be considered because, for reasons that are not understood, count suppression can sometimes be less severe using an alternative TKI. Management with an alternative TKI is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4515.html" rel="external">
          "Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other hematologic toxicities
         </strong>
         – Other TKI-associated toxicities include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Bleeding
         </strong>
         – Bleeding is generally caused by thrombocytopenia and should be managed as described above.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Gastrointestinal or other bleeding occurs in up to one-quarter of patients receiving
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         ; it is less common with other TKIs [
         <a href="#rid91">
          91-94
         </a>
         ]. Bleeding or bruising may be exacerbated by a qualitative platelet defect associated with dasatinib; such patients often have normal platelet counts and normal coagulation studies, but impaired platelet aggregation with arachidonic acid and/or
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         [
         <a href="#rid95">
          95
         </a>
         ]. The bleeding is typically mild to moderate and usually responds to a drug holiday. Dasatinib should be used with caution in patients who require anticoagulants or medications that inhibit platelet function [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Follicular lymphoid hyperplasia
         </strong>
         – Reversible follicular lymphoid hyperplasia has been reported as an uncommon event in patients taking a TKI, but the incidence is not well defined. A case series reported nine patients who developed progressive cervical lymph node enlargement while taking
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         [
         <a href="#rid96">
          96
         </a>
         ]. Lymph node biopsy demonstrated follicular lymphoid hyperplasia without evidence of extramedullary blastic transformation of CML. Discontinuation of dasatinib resulted in a complete disappearance of nodal enlargement in all patients by two months.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For patients who develop follicular lymphoid hyperplasia, we suggest holding the TKI and observing the patient for clinical improvement. A decision to again administer the same TKI after resolution should be made on a case-by-case basis.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3500683965">
         <span class="h2">
          Other toxicity
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cardiovascular
         </strong>
         – There is a substantial risk of cardiovascular (CV) and arterial thrombotic (AT) AEs in patients taking
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         . There is a slight increase of CV risk with
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         , and considerably less risk with the other TKIs used for initial treatment of CP CML. Older patients and those with pre-existing CV risk factors (eg, hypertension, diabetes, hyperlipidemia, smoking) are at greatest risk, irrespective of the TKI that is used, and the incidence ratio is highest in the early years of TKI therapy [
         <a href="#rid97">
          97-99
         </a>
         ]. CV risks with individual TKIs are discussed above. (See
         <a class="local">
          'Individual TKIs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Because most patients with CML are long-term survivors, it is important to perform a thorough baseline evaluation for CV risk factors and regular assessment and management of CV risk factors, including hypertension, lipids, and advice about smoking cessation. (See
         <a class="local">
          'Pretreatment evaluation'
         </a>
         above and
         <a class="local">
          'Monitoring toxicity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Suggestions for management of specific CV and AT AEs include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          QTc prolongation
         </strong>
         <strong>
          and dysrhythmias
         </strong>
         – Although uncommon, cardiac dysrhythmias (including prolonged QTc interval, palpitations) may occur with TKIs, and are most often seen with
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         and
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         . All patients who receive nilotinib or dasatinib should have a baseline electrocardiogram (EKG) to measure pretreatment QTc interval, correction of electrolyte abnormalities, avoidance of other medications that may prolong QTc interval  (
         <a class="graphic graphic_table graphicRef57431" href="/z/d/graphic/57431.html" rel="external">
          table 5
         </a>
         ), and dose adjustment as needed. EKG should be performed seven days after initiation of nilotinib or dasatinib, following dose adjustments, and periodically during treatment. (See
         <a class="local">
          'Nilotinib'
         </a>
         above and
         <a class="local">
          'Dasatinib'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Arterial thrombotic
         </strong>
         <strong>
          events
         </strong>
         – AT events (eg, coronary artery disease, cerebrovascular accident, peripheral artery disease) are most commonly seen with
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         , and less often with
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         . We suggest permanent discontinuation of nilotinib or dasatinib for symptomatic or progressive vascular disease. Acceptable alternatives include switching to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         or
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         or a trial of TKI discontinuation (for appropriate patients). Although a benefit is not proven, many clinicians offer low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         for general CV prophylaxis in patients taking nilotinib or dasatinib. (See
         <a class="local">
          'TKI discontinuation for TFR'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hypertension
         </strong>
         – The incidence of hypertension is increased with all TKIs but is most common with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         . Management should follow general principles. (See
         <a class="medical medical_review" href="/z/d/html/3852.html" rel="external">
          "Overview of hypertension in adults", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         CV/AT risk with the third-generation TKI,
         <a class="drug drug_general" data-topicid="87456" href="/z/d/drug information/87456.html" rel="external">
          ponatinib
         </a>
         , is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/4515.html" rel="external">
          "Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy", section on 'Ponatinib'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pulmonary
         </strong>
         – Pulmonary complications most often arise early in the course of treatment with
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         , but they can occur later and with any TKI. Patients who develop dyspnea, dry cough, or other symptoms suggestive of pleural effusion or another pulmonary process should be evaluated by chest radiograph and other testing, as clinically warranted.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pleural effusion
         </strong>
         – In some studies, up to one-third of patients treated with
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         developed pleural effusions (most often exudative) [
         <a href="#rid56">
          56
         </a>
         ]. Other causes of pleural effusion (eg, disease progression, heart failure, renal dysfunction, infection) should be investigated. Some patients have required thoracentesis, insertion of a chest tube, pleurodesis, and/or interruption or reduction of TKI dose. In a study that compared various dasatinib doses, treatment with 100 mg once daily was associated with a lower incidence of pleural effusion without affecting short- or long-term efficacy [
         <a href="#rid100">
          100
         </a>
         ]. Dasatinib-associated pleural effusion is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4336.html" rel="external">
          "Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents", section on 'Dasatinib'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pulmonary arterial hypertension
         </strong>
         – Rare cases of pulmonary arterial hypertension (PAH) have been reported among patients taking
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         [
         <a href="#rid101">
          101,102
         </a>
         ]. Dasatinib should be permanently discontinued in patients diagnosed with PAH. (See
         <a class="medical medical_review" href="/z/d/html/4336.html" rel="external">
          "Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents", section on 'Dasatinib'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/121912.html" rel="external">
          "Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Interstitial lung disease
         </strong>
         – Interstitial lung disease has also been reported in patients receiving
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/4336.html" rel="external">
          "Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents", section on 'Dasatinib'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Further description of pulmonary complications of TKIs is provided separately. (See
         <a class="medical medical_review" href="/z/d/html/4336.html" rel="external">
          "Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents", section on 'Bcr-Abl tyrosine kinase inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastrointestinal
         </strong>
         – Nausea, vomiting, and diarrhea are common early in the course of treatment with all TKIs, but especially with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         and
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         , as described above. (See
         <a class="local">
          'Common early toxicities'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Liver function
         </strong>
         – Abnormal liver function tests can occur with all TKIs but are most common with
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         and
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         . Alcohol and medications that may cause liver damage should be avoided, and dose adjustments should be made, as described for each TKI in the United States prescribing information. Additional details are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/128144.html" rel="external">
          "Chemotherapy hepatotoxicity and dose modification in patients with liver disease: Molecularly targeted agents", section on 'Specific agents'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pancreatitis
         </strong>
         – Lipase and amylase should be obtained monthly (or as clinically indicated) for the first months in patients taking
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         . (See
         <a class="local">
          'Monitoring toxicity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         For clinically significant symptoms or abnormal lipase/amylase, the TKI dose should be reduced or suspended until improvement; if symptoms or laboratory abnormalities do not improve, the patient should be treated with an alternative TKI. (See
         <a class="medical medical_review" href="/z/d/html/4515.html" rel="external">
          "Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Gastrointestinal bleeding
         </strong>
         – Management of gastrointestinal bleeding due to thrombocytopenia or a qualitative platelet disorder is described above. (See
         <a class="local">
          'Hematologic'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other toxicities
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hypophosphatemia
         </strong>
         – Hypophosphatemia has been reported in patients taking
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         or larger doses of
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         [
         <a href="#rid20">
          20,103,104
         </a>
         ]. It is unknown whether hypophosphatemia results in long-term metabolic changes in bone. One report noted increased trabecular bone volume in patients receiving long-term imatinib, which may be due to promotion of osteoblast maturation and/or inhibition of osteoclast maturation and function via inhibition of platelet-derived growth factor [
         <a href="#rid105">
          105
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Gynecomastia
         </strong>
         – In one series, gynecomastia was noted in 7 of 38 men receiving
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         and was associated with reduced levels of free testosterone [
         <a href="#rid106">
          106
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cancer
         </strong>
         – TKIs do not appear to be associated with an increased risk of second malignancy. Analysis of 1445 patients treated with a TKI for CML or other hematologic malignancy and followed for a median of 107 months reported rates of second cancers comparable to those in the Surveillance, Epidemiology, and End Results (SEER) database [
         <a href="#rid107">
          107
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H108794200">
         <span class="h1">
          TKI DISCONTINUATION FOR TFR
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients may seek a treatment-free remission (TFR) because of tyrosine kinase inhibitor (TKI) toxicity, convenience, cost of medication, a desire to become pregnant, or for other reasons.
        </p>
        <p>
         Approximately one-half of patients who meet the criteria for a trial of TKI discontinuation (described below) remain in a long-term TFR. Consequently, a sustained TFR can be anticipated in approximately 10 to 15 percent of patients with newly diagnosed CML (ie, one-half of the approximately one-third of patients who achieve a sustained, deep molecular remission).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Criteria for a trial of TKI discontinuation
         </strong>
         – Outside of a clinical trial,
         <strong>
          all
         </strong>
         of the following criteria should be met:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Age ≥18 years old
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reliably taking TKI for ≥3 years
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         No prior resistance to a second-generation (2G) TKI that required switching to another agent
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Prior evidence of a quantifiable
         <em>
          BCR::ABL1
         </em>
         transcript
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Stable molecular response (ie, MR4;
         <em>
          BCR::ABL1
         </em>
         ≤0.01 percent by the International Scale [IS])  (
         <a class="graphic graphic_table graphicRef90430" href="/z/d/graphic/90430.html" rel="external">
          table 1
         </a>
         ) for ≥2 years, as documented by ≥4 separate tests performed ≥3 months apart
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Access to a reliable quantitative polymerase chain reaction (qPCR) test that is capable of detecting at least MR4.5 and can provide results within two weeks
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects of TKI discontinuation
         </strong>
         – Aggravation or new development of musculoskeletal pain has been reported in 25 to 42 percent of patients who discontinued a TKI [
         <a href="#rid108">
          108,109
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          First six months
         </strong>
         – Monthly measurement of
         <em>
          BCR::ABL1
         </em>
         by qPCR
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Next 18 months
         </strong>
         – Every two months
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Subsequent monitoring is described below.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Response to results
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Loss of MR3 – For patients with loss of MR3 after TKI discontinuation, we suggest repeat testing within two weeks. If repeat testing confirms loss of MR3, the TKI should be resumed within four weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Monitoring by qPCR should continue every four weeks until MR4 is re-established, then every 12 weeks indefinitely. For the rare patient who fails to again achieve MR4 three months after TKI is re-initiated,
         <em>
          BCR::ABL1
         </em>
         kinase domain mutation testing should be performed. (See
         <a class="medical medical_review" href="/z/d/html/4515.html" rel="external">
          "Treatment of chronic myeloid leukemia in chronic phase after failure of initial therapy", section on 'Initial management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sustained MR3 – For patients with sustained MR3,
         <em>
          BCR::ABL1
         </em>
         should be measured by qPCR every three months. After several years of sustained MR3, we generally lengthen the monitoring interval to four to six months, but we continue testing indefinitely because late relapses (eg, &gt;2 years) have been reported [
         <a href="#rid110">
          110
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Approximately one-half of patients remain in a TFR after discontinuing a TKI, according to multiple prospective discontinuation trials. In general, patients who are most likely to maintain a long TFR are those who have had the longest period of prior TKI treatment and/or had undetectable transcript levels for many years [
         <a href="#rid111">
          111,112
         </a>
         ]. However, even among individuals who have achieved sustained MR4.5, about half will have evidence of molecular recurrence within one year after discontinuing TKI therapy, since viable CML stem cells can remain in a quiescent state in the marrow [
         <a href="#rid113">
          113-120
         </a>
         ]. Nevertheless, almost all patients who show evidence of progression can again achieve a deep molecular response upon resumption of therapy.
        </p>
        <p>
         Following are examples of studies that evaluated TKI discontinuation:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         EURO-SKI (European Stop Kinase Inhibitor) is a multicenter, prospective trial of TKI discontinuation that enrolled 758 patients in 11 countries, of whom 94 percent were taking
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         [
         <a href="#rid121">
          121
         </a>
         ]. In patients who had sustained MR3 for ≥1 year and taken a TKI for ≥3 years, molecular relapse-free survival was 50 percent (95% CI 46-54 percent) at 24 months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         LAST (Life After Stopping TKIs) is a prospective multicenter study of 173 patients in the United States who were taking
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         (60 percent of patients),
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         , or
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         and had achieved MR4.0 for ≥2 years [
         <a href="#rid122">
          122
         </a>
         ]. With a median follow-up of 42 months (4 to 62), 61 percent of patients remained in a TFR. In addition, 80, 35, 88, and 21 percent had a clinically meaning full improvement of fatigue, depression, diarrhea, and sleep disturbance, respectively. Restarting a TKI resulted in worsening of patient reported outcomes.
        </p>
        <p>
        </p>
        <p>
         Similar results have been reported by discontinuation trials in patients receiving
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         or
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         [
         <a href="#rid108">
          108,123-135
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H387764228">
         <span class="h1">
          SPECIAL SETTINGS
         </span>
        </p>
        <p class="headingAnchor" id="H2207523201">
         <span class="h2">
          Additional chromosomal abnormalities
         </span>
         <span class="headingEndMark">
          —
         </span>
         Detection of additional cytogenetic abnormalities (ACA; ie, cytogenetic abnormalities in addition to t(9;22)) at the time of diagnosis may affect response to initial treatment and influence the protocol for response monitoring. The impact of ACAs may vary with the nature of the abnormality and whether it is detected in the same cells that carry the Philadelphia chromosome (Ph) versus a separate clonal population.
        </p>
        <p>
         ACAs are reported in 5 to 10 percent of patients at the time of diagnosis of CP CML [
         <a href="#rid136">
          136
         </a>
         ]. For patients treated with tyrosine kinase inhibitors (TKI), the prognostic significance of ACAs detected at the time of diagnosis of CP CML is uncertain. This variability may reflect differences associated with specific cytogenetic abnormalities [
         <a href="#rid137">
          137-141
         </a>
         ]. It has been proposed that the more common abnormalities ("major route abnormalities") can be classified as good prognosis (eg, trisomy 8, -Y, extra copy of Ph) or poor prognosis (eg, i(17)(q10), -7/del7q, 3q26.2) [
         <a href="#rid142">
          142
         </a>
         ]. ACAs are known to be associated with adverse outcomes for patients with CP CML who were previously treated with interferon (IFN) alfa and other agents, and for patients with CML in accelerated phase or blast crisis [
         <a href="#rid137">
          137
         </a>
         ].
        </p>
        <p>
         Monitoring of the response to therapy is influenced by whether the ACA is present in the same cell as t(9;22)/
         <em>
          BCR/ABL1
         </em>
         (ie, Ph+) or in Ph-negative (Ph-) cells; metaphase cells from the initial marrow aspirate are needed to make this distinction (see
         <a class="local">
          'Pretreatment evaluation'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          ACA in Ph+ cells
         </strong>
         – If the ACA is present in the same cell as t(9;22)/
         <em>
          BCR/ABL1
         </em>
         , cases can be monitored with quantitative polymerase chain reaction (qPCR) on the blood (as described above), because the ACA will disappear as the Ph+ cells disappear. (See
         <a class="local">
          'Response monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          ACA in Ph- cells
         </strong>
         – If the ACA is present in Ph- cells, monitoring of the ACA clone will require serial bone marrow evaluations or monitoring of peripheral blood with a fluorescence in situ hybridization (FISH) probe that can detect the specific abnormality. In addition, response of CML to initial therapy must be monitored by qPCR.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1589579694">
         <span class="h2">
          Pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         TKIs are contraindicated in women who seek to become pregnant and in the first trimester of pregnancy because of increased rates of miscarriage and fetal abnormalities [
         <a href="#rid143">
          143,144
         </a>
         ]. Safety of TKIs in the second and third trimesters is not well defined. TKIs are not known to affect fertility in men or increase the rate of miscarriage or fetal abnormalities in female partners of men taking a TKI [
         <a href="#rid145">
          145-149
         </a>
         ].
        </p>
        <p>
         Conception while on a TKI and treatment with a TKI during the first trimester is strongly discouraged because of the risk of fetal abnormalities; otherwise, there is no consensus regarding optimal monitoring and management of CML during pregnancy [
         <a href="#rid150">
          150,151
         </a>
         ]. We suggest monthly monitoring
         <em>
          BCR::ABL1
         </em>
         by qPCR and initiation of treatment if
         <em>
          BCR::ABL1
         </em>
         increases to ≥1.0 percent. (See
         <a class="local">
          'Definitions of response'
         </a>
         above.)
        </p>
        <p>
         Our approach follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          First trimester
         </strong>
         – For women who require treatment in the first trimester, we suggest leukapheresis and/or IFN alfa rather than TKI therapy, because of their more favorable balance of benefit versus toxicity. IFN alfa is safe during pregnancy; some experts consider
         <a class="drug drug_general" data-topicid="8543" href="/z/d/drug information/8543.html" rel="external">
          hydroxyurea
         </a>
         safe in this setting [
         <a href="#rid150">
          150,152-157
         </a>
         ]. Low dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         and/or low molecular weight heparin may be used for thrombocytosis [
         <a href="#rid158">
          158,159
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Later pregnancy
         </strong>
         – In the second or third trimester, the potential benefit of a TKI to the mother must be weighed against risks to the fetus; IFN alfa, leukapheresis, or other approaches may be preferable in this setting.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nursing
         </strong>
         – Women should not breast feed while taking a TKI because it can pass into human breast milk and may impair growth and/or development of the infant [
         <a href="#rid160">
          160,161
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Men
         </strong>
         – We do not discontinue TKIs for male patients attempting conception. Our approach is consistent with European LeukemiaNet 2020 guidelines and opinions of other experts [
         <a href="#rid6">
          6,162,163
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         More than one-third of patients were of reproductive age at the time that CML was first diagnosed, according to a population-based registry study [
         <a href="#rid164">
          164
         </a>
         ]. A study of 180 women exposed to
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         during pregnancy reported that half of pregnancies with known outcomes were normal, but 10 percent had fetal abnormalities that ended in spontaneous abortion [
         <a href="#rid143">
          143
         </a>
         ]. Among 46 women who received
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         during pregnancy, one-third delivered a normal infant, but elective or spontaneous abortion occurred in 39 and 17 percent, respectively, 11 percent had an abnormal pregnancy, and there were fetal abnormalities in 15 percent [
         <a href="#rid144">
          144
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         Among men, some clinical studies have suggested reduced spermatogenesis with TKIs, but there are multiple reports of successful pregnancy and no increased risk for congenital abnormalities among offspring from partners of male patients receiving TKIs [
         <a href="#rid132">
          132,144,165-170
         </a>
         ]. As an example, among 17 men treated with
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         , the outcome of 14 pregnancies was known; nine patients had full term healthy babies, four had an induced abortion, and one had a spontaneous abortion [
         <a href="#rid165">
          165
         </a>
         ]. Among men treated with
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         , 91 percent of 30 female partners delivered infants who were normal at birth [
         <a href="#rid144">
          144
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H983971562">
         <span class="h2">
          Children
         </span>
         <span class="headingEndMark">
          —
         </span>
         CML is rare in children, and it accounts for &lt;3 percent of all pediatric leukemias [
         <a href="#rid171">
          171-173
         </a>
         ]. There are no evidence-based guidelines for treatment of pediatric CML, and risk stratification tools have not been validated in children. We urge participation in a clinical trial, whenever possible. Outside of a clinical trial, some experts follow guidelines designed for treatment of adult patients.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          Imatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         , and
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         are the only TKIs that are approved by the US Food and Drug Administration (FDA) for treatment of children; safety and efficacy of other TKIs in children are poorly defined. We suggest
         <strong>
          not
         </strong>
         using the clinical scoring systems to stratify pediatric treatment of CML because these models have not been validated in children. A study that evaluated 90 children with CML reported high discordance between the Sokal, Euro, and EUTOS methods [
         <a href="#rid174">
          174
         </a>
         ].
        </p>
        <p>
         Children may require decades of treatment, and it is important to monitor children for long-term side effects of TKIs, such as delayed growth, altered bone metabolism, thyroid abnormalities, and effects on puberty and fertility [
         <a href="#rid175">
          175
         </a>
         ]. Growth should be monitored closely, and an endocrinologist should be consulted for impaired longitudinal growth in children [
         <a href="#rid176">
          176-180
         </a>
         ].
        </p>
        <p>
         Studies of TKIs for treatment of pediatric CML include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imatinib
         </strong>
         – A French study included 44 children (age: 10 months to 17 years) with CP CML who were treated with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         (260 mg/m
         <sup>
          2
         </sup>
         ) [
         <a href="#rid181">
          181
         </a>
         ]. With median follow-up of 31 months, the rate of complete hematologic response (CHR) was 98 percent, and estimated progression-free survival (PFS) at 36 months was 98 percent. After 12 months, rates of complete cytogenetic response (CCyR) and major molecular response (MMR) were 61 and 31 percent, respectively. Early molecular response (ie,
         <em>
          BCR::ABL1
         </em>
         10 percent [International Scale (IS)] at three months) correlated with better PFS and higher rates of CCyR and MMR at 12 months [
         <a href="#rid182">
          182
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         An Italian study of 47 children with CP CML reported that higher dose
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         (340 mg/m
         <sup>
          2
         </sup>
         ) was effective and well tolerated [
         <a href="#rid183">
          183,184
         </a>
         ]. CCyR was achieved in 92 percent at six months, and at 12 months MMR (≤0.01 percent
         <em>
          BCR::ABL1
         </em>
         IS) and MR4 were achieved in 67 and 33 percent of patients, respectively.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dasatinib
         </strong>
         –
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          Dasatinib
         </a>
         (60 mg/m² to 120 mg/m²) was tolerated in a study of children with newly diagnosed, relapsed, or refractory CML [
         <a href="#rid185">
          185
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          Imatinib
         </a>
         is approved by the FDA in children and
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         is approved by the FDA for patients age ≥1 year.
        </p>
        <p>
         There are no reports of TKI discontinuation in children.
        </p>
        <p class="headingAnchor" id="H931317495">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117207.html" rel="external">
          "Society guideline links: Chronic myeloid leukemia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3033673346">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/15792.html" rel="external">
          "Patient education: Chronic myeloid leukemia (CML) (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/684.html" rel="external">
          "Patient education: Chronic myeloid leukemia (CML) in adults (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2526973221">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Description
         </strong>
         – Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm that is associated with the Philadelphia chromosome t(9;22)(q34;q11) and the
         <em>
          BCR::ABL1
         </em>
         fusion gene, which produces a constitutively active BCR::ABL1 tyrosine kinase. Chronic phase (CP) CML can progress from a relatively indolent disorder to accelerated phase (AP) or blast crisis (BC).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Goals of treatment
         </strong>
         – The goals for management of CP CML are to achieve clinical remission, maintain long-term disease control, and avoid disease progression to AP or BC, while optimizing quality of life by limiting treatment-related toxicity. For patients who achieve a sustained and deep molecular remission, a trial of discontinuation of therapy to achieve a treatment-free remission (TFR) is a long-term goal of management. (See
         <a class="local">
          'Goals of care'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pretreatment evaluation
         </strong>
         – Pretreatment evaluation should include history, physical examination, specific laboratory studies, and determination of CML risk category (using either the Sokal, Euro, EUTOS, or ELTS tools)  (
         <a class="graphic graphic_table graphicRef60446" href="/z/d/graphic/60446.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'Pretreatment evaluation'
         </a>
         above and
         <a class="local">
          'CML risk score'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment with a tyrosine kinase inhibitor (TKI)
         </strong>
         – With the exception of CML diagnosed during pregnancy, we recommend a BCR::ABL1 TKI for initial treatment of all patients with CP CML (
         <a class="grade" href="https:///uptodate/show/grade_1" rel="external">
          Grade 1A
         </a>
         ), based on superior treatment outcomes and modest toxicity compared with other treatments (eg, cytotoxic agents, interferons, hematopoietic cell transplantation). (See
         <a class="local">
          'Rationale for TKI treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choosing a TKI
         </strong>
         – We stratify selection of a BCR::ABL1 TKI according to the CML risk score and the goal of achieving a TFR. No individual TKI is preferred for initial treatment of all patients with CP CML. The choice of a particular TKI must also consider the side effect profile  (
         <a class="graphic graphic_table graphicRef89930" href="/z/d/graphic/89930.html" rel="external">
          table 4
         </a>
         ), comorbid illnesses, availability, cost, and patient preference (see
         <a class="local">
          'CML risk score'
         </a>
         above and
         <a class="local">
          'Choosing a TKI'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          High-risk CML
         </strong>
         – For patients with high-risk CP CML, we suggest treatment with a second-generation (2G) TKI (eg,
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         ), when available, rather than
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). Progression to AP/BC is a concern in patients with high-risk CML and, compared with imatinib, 2G TKIs may be associated with lower rates of disease progression. However, imatinib and 2G TKIs produce comparable rates of overall survival (OS), progression-free survival (PFS), and adverse events (AE) in high-risk CML.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Low- or intermediate-risk CML
         </strong>
         – For patients with low-risk or intermediate-risk CP CML, the choice of a TKI is influenced by the importance assigned to achievement of a TFR  (
         <a class="graphic graphic_algorithm graphicRef130520" href="/z/d/graphic/130520.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          TFR is an important goal
         </strong>
         – For patients with low- or intermediate-risk CP CML who consider a TFR an important goal, we suggest a 2G TKI (eg,
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         ) rather than
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ), because 2G TKIs are associated with faster and deeper responses and are more likely to enable a trial of TKI discontinuation. (See
         <a class="local">
          'TFR is an important goal'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         Eligibility criteria for a trial of TKI discontinuation and outcomes are described above. (See
         <a class="local">
          'TKI discontinuation for TFR'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          TFR is NOT an important goal
         </strong>
         – For patients who do
         <strong>
          not
         </strong>
         consider achieving a TFR a high priority, treatment with
         <a class="drug drug_general" data-topicid="8961" href="/z/d/drug information/8961.html" rel="external">
          imatinib
         </a>
         or a 2G TKI (eg,
         <a class="drug drug_general" data-topicid="9448" href="/z/d/drug information/9448.html" rel="external">
          nilotinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="8852" href="/z/d/drug information/8852.html" rel="external">
          dasatinib
         </a>
         ,
         <a class="drug drug_general" data-topicid="86371" href="/z/d/drug information/86371.html" rel="external">
          bosutinib
         </a>
         ) is acceptable, because they achieve comparable rates of OS, PFS, and AEs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dose, toxicities, and outcomes
         </strong>
         – Initial treatment dose, toxicities, and outcomes with individual TKIs are presented for the individual TKIs. (See
         <a class="local">
          'Individual TKIs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring
         </strong>
         – We monitor response to TKI therapy with serial measurement of
         <em>
          BCR::ABL1
         </em>
         by quantitative polymerase chain reaction (qPCR) in peripheral blood, cytogenetics, and hematologic parameters at regular intervals  (
         <a class="graphic graphic_algorithm graphicRef140486" href="/z/d/graphic/140486.html" rel="external">
          algorithm 3
         </a>
         ), as described above. (See
         <a class="local">
          'Response monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxicity
         </strong>
         – Management of TKI toxicity is crucial for maintaining treatment adherence and achieving optimal outcomes. Some toxicities are common to all TKIs (eg, cytopenias, rash, nausea, fatigue, muscle cramps), but each agent is also associated with certain "defining" toxicities. Examples of defining toxicities include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Imatinib – Muscle cramps, fatigue, edema, nausea, diarrhea
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Nilotinib – Cardiovascular (CV) toxicity (including coronary, cerebral, and peripheral vascular disease), prolonged QTc interval, hyperglycemia, pancreatitis
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Dasatinib – Pleural effusion, pulmonary hypertension, prolonged QTc interval, platelet dysfunction
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bosutinib – Diarrhea, abnormal liver function, rash
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Our approach to managing TKI toxicity is discussed above. (See
         <a class="local">
          'Managing toxicity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment-free remission
         </strong>
         – For patients who achieve a long-standing, deep molecular response and are expected to comply with the demands of frequent testing and follow-up, a trial of TKI discontinuation is an acceptable option. Criteria for a TKI discontinuation trial and management are discussed above. (See
         <a class="local">
          'TKI discontinuation for TFR'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pregnancy
         </strong>
         – TKIs are contraindicated in women who seek to become pregnant, in early pregnancy, and in nursing mothers because of increased rates of miscarriage/fetal abnormalities and potential effects of growth and development in infants. There are no restrictions for men who wish to father a child while on TKI therapy. Management of CML in pregnancy and in children is discussed above. (See
         <a class="local">
          'Pregnancy'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984; 63:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998; 90:850.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011; 118:686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfirrmann M, Baccarani M, Saussele S, et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 2016; 30:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfirrmann M, Clark RE, Prejzner W, et al. The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia. Leukemia 2020; 34:2138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hochhaus A, Baccarani M, Silver RT, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 2020; 34:966.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Radivoyevitch T, Weaver D, Hobbs B, et al. Do persons with chronic myeloid leukaemia have normal or near normal survival? Leukemia 2020; 34:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hehlmann R, Lauseker M, Saußele S, et al. Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants. Leukemia 2017; 31:2398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bower H, Björkholm M, Dickman PW, et al. Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J Clin Oncol 2016; 34:2851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011; 103:553.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kenzik KM, Bhatia R, Williams GR, Bhatia S. Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia. Cancer 2019; 125:2570.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hochhaus A, Larson RA, Guilhot F, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. N Engl J Med 2017; 376:917.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia 2016; 30:1044.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. J Clin Oncol 2016; 34:2333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol 2018; 36:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yun S, Vincelette ND, Segar JM, et al. Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials. Clin Lymphoma Myeloma Leuk 2016; 16:e85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hughes TP, Saglio G, Larson RA, et al. Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: ENESTnd 10-Year Analysis [Abstract #632]. Blood (ASH Annual Meeting Abstracts) 2019; 134:2924.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saglio G, Jabbour E. First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI. Leuk Lymphoma 2018; 59:1523.
          </a>
         </li>
         <li class="breakAll">
          Imatinib mesylate tablets. United States prescribing information. Revised September 2016. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021588s047lbl.pdf (Accessed on February 27, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006; 354:2006.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berman E, Girotra M, Cheng C, et al. Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors. Leuk Res 2013; 37:790.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348:994.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kantarjian HM, Cortes JE, O'Brien S, et al. Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses. Blood 2003; 101:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349:1423.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hahn EA, Glendenning GA, Sorensen MV, et al. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol 2003; 21:2138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355:2408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deininger M, O'Brien SG, Guilhot F, et al. International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib (abstract 1126). Blood 2009; 114:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006; 108:1478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeung DT, Osborn MP, White DL, et al. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood 2015; 125:915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braziel RM, Launder TM, Druker BJ, et al. Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience. Blood 2002; 100:435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasserjian RP, Boecklin F, Parker S, et al. ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. Am J Clin Pathol 2002; 117:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deininger MW, O'Brien SG, Ford JM, Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003; 21:1637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosti G, Martinelli G, Bassi S, et al. Molecular response to imatinib in late chronic-phase chronic myeloid leukemia. Blood 2004; 103:2284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palandri F, Iacobucci I, Martinelli G, et al. Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. J Clin Oncol 2008; 26:106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hochhaus A, Druker B, Sawyers C, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 2008; 111:1039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hess G, Meyer RG, Schuch B, et al. Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: a 5-year follow up. Am J Hematol 2008; 83:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kantarjian H, O'Brien S, Garcia-Manero G, et al. Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy. Cancer 2012; 118:3116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26:3358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baccarani M, Rosti G, Castagnetti F, et al. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. Blood 2009; 113:4497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortes JE, Baccarani M, Guilhot F, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010; 28:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010; 363:2511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gardembas M, Rousselot P, Tulliez M, et al. Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase. Blood 2003; 102:4298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deenik W, van der Holt B, Verhoef GE, et al. Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia. Blood 2008; 111:2581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deenik W, Janssen JJ, van der Holt B, et al. Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia. Haematologica 2010; 95:914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simonsson B, Gedde-Dahl T, Markevärn B, et al. Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia. Blood 2011; 118:3228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosti G, Palandri F, Castagnetti F, et al. Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. Blood 2009; 114:4933.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hehlmann R, Lauseker M, Jung-Munkwitz S, et al. Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011; 29:1634.
          </a>
         </li>
         <li class="breakAll">
          Nilotinib capsules. United States prescribing information. Revised June 2010. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022068s004s005lbl.pdf (Accessed on January 02, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362:2251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kantarjian HM, Hochhaus A, Saglio G, et al. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol 2011; 12:841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Larson RA, Hochhaus A, Hughes TP, et al. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 2012; 26:2197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hochhaus A, Saglio G, Larson RA, et al. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2013; 121:3703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang J, Shen ZX, Saglio G, et al. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood 2015; 125:2771.
          </a>
         </li>
         <li class="breakAll">
          Dasatinib tablet. United States prescribing information. Revised October 2010. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021986s7s8lbl.pdf (Accessed on January 04, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schiffer CA, Cortes JE, Hochhaus A, et al. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. Cancer 2016; 122:1398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Radich JP, Kopecky KJ, Appelbaum FR, et al. A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia. Blood 2012; 120:3898.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362:2260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 2014; 123:494.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kantarjian HM, Shah NP, Cortes JE, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012; 119:1123.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naqvi K, Jabbour E, Skinner J, et al. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 2020; 126:67.
          </a>
         </li>
         <li class="breakAll">
          Bosutinib tablets. United States prescribing information. Revised December 2017. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/203341s009lbl.pdf (Accessed on February 26, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortes JE, Apperley JF, DeAngelo DJ, et al. Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review. J Hematol Oncol 2018; 11:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012; 30:3486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brümmendorf TH, Cortes JE, de Souza CA, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol 2015; 168:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwak JY, Kim SH, Oh SJ, et al. Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. Clin Cancer Res 2017; 23:7180.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang L, Meng L, Liu B, et al. Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study. Clin Cancer Res 2021; 27:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013; 122:872.
          </a>
         </li>
         <li class="breakAll">
          https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf (Accessed on January 22, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cross NC, White HE, Müller MC, et al. Standardized definitions of molecular response in chronic myeloid leukemia. Leukemia 2012; 26:2172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999; 131:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douet-Guilbert N, Morel F, Le Charpentier T, et al. Interphase FISH for follow-up of Philadelphia chromosome-positive chronic myeloid leukemia treatment. Anticancer Res 2004; 24:2535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Testoni N, Marzocchi G, Luatti S, et al. Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP. Blood 2009; 114:4939.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lima L, Bernal-Mizrachi L, Saxe D, et al. Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond. Cancer 2011; 117:1245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark RE, Polydoros F, Apperley JF, et al. De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial. Lancet Haematol 2017; 4:e310.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hirji I, Gupta S, Goren A, et al. Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective. Health Qual Life Outcomes 2013; 11:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010; 28:2381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Efficace F, Baccarani M, Breccia M, et al. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 2011; 118:4554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Williams LA, Garcia Gonzalez AG, Ault P, et al. Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood 2013; 122:641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kekäle M, Peltoniemi M, Airaksinen M. Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment. Patient Prefer Adherence 2015; 9:1733.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beaumont JL, Magestro M, Coombs J, et al. Assessment of Patient Reported Outcomes (PROs) From the Enestnd Trial with Minimum Follow-up of 36 Cycles. Blood (ASH Annual Meeting Abstracts, Abstract 3166) 2012; 120:3166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Labeit AM, Copland M, Cork LM, et al. Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia. Blood (ASH Annual Meeting Abstracts) 2015; 126:4024.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brouard M, Saurat JH. Cutaneous reactions to STI571. N Engl J Med 2001; 345:618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsiao LT, Chung HM, Lin JT, et al. Stevens-Johnson syndrome after treatment with STI571: a case report. Br J Haematol 2002; 117:620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rule SA, O'Brien SG, Crossman LC. Managing cutaneous reactions to imatinib therapy. Blood 2002; 100:3434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Valeyrie L, Bastuji-Garin S, Revuz J, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol 2003; 48:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood 2007; 110:2828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Santos FP, Alvarado Y, Kantarjian H, et al. Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib. Cancer 2011; 117:982.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quintás-Cardama A, Kantarjian H, Ravandi F, et al. Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 2009; 115:2482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354:2531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortes J, Rousselot P, Kim DW, et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 2007; 109:3207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gratacap MP, Martin V, Valéra MC, et al. The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood 2009; 114:1884.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quintás-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia. Blood 2009; 114:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roux C, Nicolini FE, Rea D, et al. Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase. Blood 2013; 122:3082.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jain P, Kantarjian H, Boddu PC, et al. Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs. Blood Adv 2019; 3:851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aghel N, Delgado DH, Lipton JH. Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines? Leukemia 2018; 32:2095.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Assunção PM, Lana TP, Delamain MT, et al. Cardiovascular Risk and Cardiovascular Events in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors. Clin Lymphoma Myeloma Leuk 2019; 19:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Porkka K, Khoury HJ, Paquette RL, et al. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer 2010; 116:377.
          </a>
         </li>
         <li class="breakAll">
          http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm275176.htm (Accessed on October 11, 2011).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125:2128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hazarika M, Jiang X, Liu Q, et al. Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 2008; 14:5325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osorio S, Noblejas AG, Durán A, Steegmann JL. Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response. Am J Hematol 2007; 82:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fitter S, Dewar AL, Kostakis P, et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood 2008; 111:2538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gambacorti-Passerini C, Tornaghi L, Cavagnini F, et al. Gynaecomastia in men with chronic myeloid leukaemia after imatinib. Lancet 2003; 361:1954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verma D, Kantarjian H, Strom SS, et al. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood 2011; 118:4353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hochhaus A, Masszi T, Giles FJ, et al. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia 2017; 31:1525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee SE, Choi SY, Song HY, et al. Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study. Haematologica 2016; 101:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rousselot P, Loiseau C, Delord M, et al. Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission. Blood Adv 2020; 4:3034.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahon FX, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010; 11:1029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Imagawa J, Tanaka H, Okada M, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol 2015; 2:e528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michor F, Hughes TP, Iwasa Y, et al. Dynamics of chronic myeloid leukaemia. Nature 2005; 435:1267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Angstreich GR, Matsui W, Huff CA, et al. Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors. Br J Haematol 2005; 130:373.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huff CA, Matsui W, Smith BD, Jones RJ. The paradox of response and survival in cancer therapeutics. Blood 2006; 107:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006; 107:4532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graham SM, Jørgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhatia R, Holtz M, Niu N, et al. Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003; 101:4701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 2007; 109:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol 2014; 32:424.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol 2018; 19:747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atallah E, Schiffer CA, Radich JP, et al. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial. JAMA Oncol 2021; 7:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Etienne G, Guilhot J, Rea D, et al. Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia. J Clin Oncol 2017; 35:298.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross DM, Branford S, Seymour JF, et al. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 2013; 122:515.
          </a>
         </li>
         <li class="breakAll">
          Nilotinib capsules. United States prescribing information. Revised December 2017. US Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022068s026lbl.pdf (Accessed on January 13, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mauro MJ, Druker BJ, Maziarz RT. Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission. Leuk Res 2004; 28 Suppl 1:S71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghanima W, Kahrs J, Dahl TG 3rd, Tjonnfjord GE. Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia. Eur J Haematol 2004; 72:441.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Higashi T, Tsukada J, Kato C, et al. Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases. Am J Hematol 2004; 76:275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004; 104:2204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ali R, Ozkalemkaş F, Ozçelik T, et al. Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML). Outcome of discontinuation of imatinib therapy after achieving a molecular remission. Leuk Res 2005; 29:971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Merante S, Orlandi E, Bernasconi P, et al. Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation. Haematologica 2005; 90:979.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ault P, Kantarjian H, O'Brien S, et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol 2006; 24:1204.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hess G, Bunjes D, Siegert W, et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol 2005; 23:7583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thielen N, van der Holt B, Cornelissen JJ, et al. Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON). Eur J Cancer 2013; 49:3242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rea D, Nicolini FE, Tulliez M, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood 2017; 129:846.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaccaria A, Testoni N, Valenti AM, et al. Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. Cancer Genet Cytogenet 2010; 199:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortes JE, Talpaz M, Giles F, et al. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003; 101:3794.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schoch C, Haferlach T, Kern W, et al. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia 2003; 17:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortes JE, Talpaz M, O'Brien S, et al. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer 2006; 106:1306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luatti S, Castagnetti F, Marzocchi G, et al. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. Blood 2012; 120:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fabarius A, Leitner A, Hochhaus A, et al. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 2011; 118:6760.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang W, Cortes JE, Tang G, et al. Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood 2016; 127:2742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pye SM, Cortes J, Ault P, et al. The effects of imatinib on pregnancy outcome. Blood 2008; 111:5505.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortes JE, Abruzzese E, Chelysheva E, et al. The impact of dasatinib on pregnancy outcomes. Am J Hematol 2015; 90:1111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramasamy K, Hayden J, Lim Z, et al. Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. Br J Haematol 2007; 137:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breccia M, Cannella L, Montefusco E, et al. Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases. Leuk Res 2008; 32:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oweini H, Otrock ZK, Mahfouz RA, Bazarbachi A. Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib. Arch Gynecol Obstet 2011; 283:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghalaut VS, Prakash G, Bansal P, et al. Effect of imatinib on male reproductive hormones in BCR-ABL positive CML patients: A preliminary report. J Oncol Pharm Pract 2014; 20:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alizadeh H, Jaafar H, Rajnics P, et al. Outcome of pregnancy in chronic myeloid leukaemia patients treated with tyrosine kinase inhibitors: short report from a single centre. Leuk Res 2015; 39:47.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koh LP, Kanagalingam D. Pregnancies in patients with chronic myeloid leukemia in the era of imatinib. Int J Hematol 2006; 84:459.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Palani R, Milojkovic D, Apperley JF. Managing pregnancy in chronic myeloid leukaemia. Ann Hematol 2015; 94 Suppl 2:S167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haggstrom J, Adriansson M, Hybbinette T, et al. Two cases of CML treated with alpha-interferon during second and third trimester of pregnancy with analysis of the drug in the new-born immediately postpartum. Eur J Haematol 1996; 57:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuroiwa M, Gondo H, Ashida K, et al. Interferon-alpha therapy for chronic myelogenous leukemia during pregnancy. Am J Hematol 1998; 59:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lipton JH, Derzko CM, Curtis J. Alpha-interferon and pregnancy in a patient with CML. Hematol Oncol 1996; 14:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baykal C, Zengin N, Coşkun F, et al. Use of hydroxyurea and alpha-interferon in chronic myeloid leukemia during pregnancy: a case report. Eur J Gynaecol Oncol 2000; 21:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thauvin-Robinet C, Maingueneau C, Robert E, et al. Exposure to hydroxyurea during pregnancy: a case series. Leukemia 2001; 15:1309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fadilah SA, Ahmad-Zailani H, Soon-Keng C, Norlaila M. Successful treatment of chronic myeloid leukemia during pregnancy with hydroxyurea. Leukemia 2002; 16:1202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           James AH, Brancazio LR, Price T. Aspirin and reproductive outcomes. Obstet Gynecol Surv 2008; 63:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deruelle P, Coulon C. The use of low-molecular-weight heparins in pregnancy--how safe are they? Curr Opin Obstet Gynecol 2007; 19:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Russell MA, Carpenter MW, Akhtar MS, et al. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol 2007; 27:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ali R, Ozkalemkas F, Kimya Y, et al. Imatinib use during pregnancy and breast feeding: a case report and review of the literature. Arch Gynecol Obstet 2009; 280:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abruzzese E, Mauro M, Apperley J, Chelysheva E. Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations. Ther Adv Hematol 2020; 11:2040620720966120.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baccarani M, Abruzzese E, Accurso V, et al. Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. Blood Adv 2019; 3:4280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffmann VS, Baccarani M, Hasford J, et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia 2015; 29:1336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cortes JE, Gambacorti-Passerini C, Deininger M, et al. Pregnancy outcomes in patients treated with bosutinib. Int J Hematol Oncol 2020; 9:IJH26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang X, Zhou L, Chen X, et al. Impact of Imatinib on the Fertility of Male Patients with Chronic Myelogenous Leukaemia in the Chronic Phase. Target Oncol 2017; 12:827.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abruzzese E, Aureli S, Bondanini F, et al. Chronic Myeloid Leukemia and Pregnancy: When Dreams Meet Reality. State of the Art, Management and Outcome of 41 Cases, Nilotinib Placental Transfer. J Clin Med 2022; 11.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicolini FE, Alcazer V, Huguet F, et al. CML patients show sperm alterations at diagnosis that are not improved with imatinib treatment. Leuk Res 2016; 48:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rambhatla A, Strug MR, De Paredes JG, et al. Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review. J Assist Reprod Genet 2021; 38:1897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szakács Z, Hegyi PJ, Farkas N, et al. Pregnancy outcomes of women whom spouse fathered children after tyrosine kinase inhibitor therapy for chronic myeloid leukemia: A systematic review. PLoS One 2020; 15:e0243045.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de la Fuente J, Baruchel A, Biondi A, et al. Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years. Br J Haematol 2014; 167:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hijiya N, Millot F, Suttorp M. Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions. Pediatr Clin North Am 2015; 62:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hijiya N, Schultz KR, Metzler M, et al. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood 2016; 127:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gurrea Salas D, Glauche I, Tauer JT, et al. Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients? Ann Hematol 2015; 94:1363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Samis J, Lee P, Zimmerman D, et al. Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia. Pediatr Blood Cancer 2016; 63:1332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shima H, Tokuyama M, Tanizawa A, et al. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J Pediatr 2011; 159:676.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bansal D, Shava U, Varma N, et al. Imatinib has adverse effect on growth in children with chronic myeloid leukemia. Pediatr Blood Cancer 2012; 59:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rastogi MV, Stork L, Druker B, et al. Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia. Pediatr Blood Cancer 2012; 59:840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Narayanan KR, Bansal D, Walia R, et al. Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis. Pediatr Blood Cancer 2013; 60:1148.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suttorp M, Millot F. Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation. Hematology Am Soc Hematol Educ Program 2010; 2010:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Millot F, Baruchel A, Guilhot J, et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. J Clin Oncol 2011; 29:2827.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Millot F, Guilhot J, Baruchel A, et al. Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study. Blood 2014; 124:2408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Champagne MA, Fu CH, Chang M, et al. Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer 2011; 57:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giona F, Putti MC, Micalizzi C, et al. Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience. Br J Haematol 2015; 170:398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zwaan CM, Rizzari C, Mechinaud F, et al. Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium. J Clin Oncol 2013; 31:2460.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 4508 Version 54.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6584184" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Prognostic discrimination in "good-risk" chronic granulocytic leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9625174" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21536864" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26416462" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32601376" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32127639" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31862960" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Do persons with chronic myeloid leukaemia have normal or near normal survival?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28804124" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27325849" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21422402" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30973642" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28273028" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26837842" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27217448" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29091516" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27101984" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: ENESTnd 10-Year Analysis [Abstract #632]
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28972424" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28972424" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16687713" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Altered bone and mineral metabolism in patients receiving imatinib mesylate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23473999" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12637609" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12393600" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14534335" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12775739" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17151364" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib (abstract 1126).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16627756" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25519749" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11287972" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12091333" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11888075" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11870241" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12668652" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Practical management of patients with chronic myeloid leukemia receiving imatinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14645009" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Molecular response to imatinib in late chronic-phase chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18165644" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17932248" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17876770" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: a 5-year follow up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22370904" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18519952" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19264678" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20008622" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21175313" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12933584" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Results of a prospective phase 2 study combining imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukemia in chronic phase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18172005" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20015886" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21685374" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19822896" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21422420" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-αin newly diagnosed chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21422420" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-αin newly diagnosed chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20525993" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21856226" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22699418" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23502220" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25766724" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25766724" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26998677" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22915637" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20525995" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24311723" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22160483" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31553487" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31553487" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30587215" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22949154" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25196702" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28939746" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32928796" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23803709" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23803709" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22504141" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Standardized definitions of molecular response in chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10428738" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Chronic myelogenous leukemia: biology and therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15330210" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Interphase FISH for follow-up of Philadelphia chromosome-positive chronic myeloid leukemia treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19797518" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21381013" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Peripheral blood monitoring of chronic myeloid leukemia during treatment with imatinib, second-line agents, and beyond.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16522812" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28566209" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24099272" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20385986" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21750313" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23777764" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Measuring the symptom burden associated with the treatment of chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26677317" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Patient-reported adverse drug reactions and their influence on adherence and quality of life of chronic myeloid leukemia patients on per oral tyrosine kinase inhibitor treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Assessment of Patient Reported Outcomes (PROs) From the Enestnd Trial with Minimum Follow-up of 36 Cycles
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11529225" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Cutaneous reactions to STI571.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12028031" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Stevens-Johnson syndrome after treatment with STI571: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12412577" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Managing cutaneous reactions to imatinib therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12582389" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17626839" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : How I treat chronic myeloid leukemia in the imatinib era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20960502" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19280591" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16775234" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17185463" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19494352" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19414863" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24159167" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Reversible lymph node follicular hyperplasia associated with dasatinib treatment of chronic myeloid leukemia in chronic phase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30885996" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30201984" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : Cardiovascular events in chronic myeloid leukemia clinical trials. Is it time to reassess and report the events according to cardiology guidelines?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30660512" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Cardiovascular Risk and Cardiovascular Events in Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19924787" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19924787" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22451584" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Pulmonary arterial hypertension in patients treated by dasatinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18765523" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Tasigna for chronic and accelerated phase Philadelphia chromosome--positive chronic myelogenous leukemia resistant to or intolerant of imatinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17117416" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18042796" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Long-term imatinib therapy promotes bone formation in CML patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12801741" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Gynaecomastia in men with chronic myeloid leukaemia after imatinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21846902" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28218239" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26888022" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32614963" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20965785" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26686407" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15988530" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Dynamics of chronic myeloid leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16042686" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16150939" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : The paradox of response and survival in cancer therapeutics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16469872" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11756187" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12576334" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16973963" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24323036" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29735299" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33180106" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28095277" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23704092" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23704092" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15036945" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15128424" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Sustained cytogenetic response after discontinuation of imatinib mesylate in a patient with chronic myeloid leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15224366" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15377577" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Discontinuation of imatinib therapy after achieving a molecular response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15978950" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML). Outcome of discontinuation of imatinib therapy after achieving a molecular remission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15996937" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Outcome of four patients with chronic myeloid leukemia after imatinib mesylate discontinuation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16446320" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Pregnancy among patients with chronic myeloid leukemia treated with imatinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16234522" id="rid132" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          133 : Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23876833" id="rid133" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          134 : Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27932374" id="rid134" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          135 : Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20471509" id="rid135" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          136 : Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12560227" id="rid136" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          137 : Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12592348" id="rid137" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          138 : Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16463391" id="rid138" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          139 : Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22692507" id="rid139" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          140 : Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22039253" id="rid140" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          141 : Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27006386" id="rid141" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          142 : Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18322153" id="rid142" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          143 : The effects of imatinib on pregnancy outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26348106" id="rid143" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          144 : The impact of dasatinib on pregnancy outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17408403" id="rid144" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          145 : Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17804066" id="rid145" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          146 : Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20473616" id="rid146" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          147 : Successful pregnancy involving a man with chronic myeloid leukemia on dasatinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23966360" id="rid147" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          148 : Effect of imatinib on male reproductive hormones in BCR-ABL positive CML patients: A preliminary report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25455655" id="rid148" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          149 : Outcome of pregnancy in chronic myeloid leukaemia patients treated with tyrosine kinase inhibitors: short report from a single centre.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17189230" id="rid149" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          150 : Pregnancies in patients with chronic myeloid leukemia in the era of imatinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25814083" id="rid150" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          151 : Managing pregnancy in chronic myeloid leukaemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8698119" id="rid151" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          152 : Two cases of CML treated with alpha-interferon during second and third trimester of pregnancy with analysis of the drug in the new-born immediately postpartum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9723590" id="rid152" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          153 : Interferon-alpha therapy for chronic myelogenous leukemia during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9119356" id="rid153" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          154 : Alpha-interferon and pregnancy in a patient with CML.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10726630" id="rid154" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          155 : Use of hydroxyurea and alpha-interferon in chronic myeloid leukemia during pregnancy: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11480579" id="rid155" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          156 : Exposure to hydroxyurea during pregnancy: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12040456" id="rid156" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          157 : Successful treatment of chronic myeloid leukemia during pregnancy with hydroxyurea.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18081940" id="rid157" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          158 : Aspirin and reproductive outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18007136" id="rid158" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          159 : The use of low-molecular-weight heparins in pregnancy--how safe are they?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17377606" id="rid159" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          160 : Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19083009" id="rid160" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          161 : Imatinib use during pregnancy and breast feeding: a case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33194164" id="rid161" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          162 : Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31869412" id="rid162" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          163 : Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25783795" id="rid163" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          164 : The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33005329" id="rid164" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          165 : Pregnancy outcomes in patients treated with bosutinib.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28791527" id="rid165" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          166 : Impact of Imatinib on the Fertility of Male Patients with Chronic Myelogenous Leukaemia in the Chronic Phase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35407407" id="rid166" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          167 : Chronic Myeloid Leukemia and Pregnancy: When Dreams Meet Reality. State of the Art, Management and Outcome of 41 Cases, Nilotinib Placental Transfer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27501271" id="rid167" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          168 : CML patients show sperm alterations at diagnosis that are not improved with imatinib treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33826052" id="rid168" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          169 : Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33270732" id="rid169" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          170 : Pregnancy outcomes of women whom spouse fathered children after tyrosine kinase inhibitor therapy for chronic myeloid leukemia: A systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24976289" id="rid170" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          171 : Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25435115" id="rid171" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          172 : Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26511135" id="rid172" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          173 : Pediatric chronic myeloid leukemia is a unique disease that requires a different approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25894600" id="rid173" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          174 : Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27100618" id="rid174" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          175 : Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21592517" id="rid175" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          176 : Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22052850" id="rid176" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          177 : Imatinib has adverse effect on growth in children with chronic myeloid leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22378641" id="rid177" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          178 : Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23322583" id="rid178" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          179 : Growth failure in children with chronic myeloid leukemia receiving imatinib is due to disruption of GH/IGF-1 axis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21239821" id="rid179" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          180 : Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stem-cell transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21670449" id="rid180" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          181 : Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25170123" id="rid181" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          182 : Impact of early molecular response in children with chronic myeloid leukemia treated in the French Glivec phase 4 study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21465636" id="rid182" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          183 : Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25891192" id="rid183" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          184 : Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23715577" id="rid184" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          185 : Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
